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Directed Evolution of Peptide Inhibitors of HIV-1 Entry 
 
Abstract 
 
The conflict between HIV-1 and the host immune system plays out over a time-
scale of months and years, and on a grander scale in the co-evolution of lentiviruses and 
the immune systems of their host species.  Directed evolution of HIV-1 entry inhibitors 
using controlled randomization together with a display system offers a means of 
recapitulating one side of this conflict in vitro on an accelerated time-scale.  To address 
limitations in existing display systems, we constructed a vector (pDQ1) integrating 
phage-display and mammalian-expression systems.  This vector displays on phage when 
expressed in bacteria, and as an Fc-fusion when expressed in tissue culture, thus 
accelerating the iterative process of randomization, display, and characterization.  We 
demonstrated the utility of this vector in the evolution of a CD4-mimetic peptide. 
The HIV-1 envelope glycoprotein (Env) is the sole viral protein expressed on the 
surface of the virion, and it is subject to neutralization by the host antibody response.  In 
adapting to this pressure Env has acquired inherent resistance to neutralization: Env has 
evolved such that its accessible epitopes are poorly conserved and its conserved epitopes 
are poorly accessible.  Two epitopes are constrained by the need to interact with host 
proteins: the receptor- and coreceptor-binding sites.  Access to these conserved sites is 
limited for molecules the size of antibodies.  Targeting the binding sites with receptor-
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mimetic peptides sidesteps accessibility issues in a way not possible for antibodies, while 
retaining access to the molecular toolbox of display technologies.    
Using the pDQ1 vector, we adapted a natively-expressed version of a CD4-
mimetic previously developed using non-natural amino acids.  Development of a high-
affinity natively-expressible peptide allowed for the fusion of this element to a tyrosine-
sulfated CCR5 coreceptor-mimetic peptide to generate a double-mimetic peptide.  
Optimization of linker length and direction allowed for simultaneous binding of the 
double-mimetic to receptor- and coreceptor-binding sites.  We characterized the CD4-
mimetic and the double-mimetic peptides with binding, receptor-complementation and 
neutralization assays.  Inclusion of a coreceptor-mimetic peptide improved avidity and 
eliminated CD4-like enhancement of viral infection.  Our studies indicate that there is 
significant advantage to simultaneously targeting both conserved Env epitopes. 
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1. A.  THE VIRAL LIFECYCLE 
A Basic Overview of the HIV-1 Lifecycle 
Viral entry.  HIV-1 infection of a host cell begins with viral entry.  The 
membranes of enveloped viruses, and the membranes of the cells they infect, are 
composed largely of lipids with negatively charged head groups.  For viral entry to occur 
the virus must first overcome the tendency of these bilayers to repel one another [1].  The 
HIV-1 envelope glycoprotein (Env), the one viral protein exposed on the viral surface, 
must first attach to the cell by engaging in low affinity interactions with cellular surface 
molecules, which serve as attachment factors.  Examples of these include the lectin DC-
SIGN, an integrin (α4β7integrin), as well as a number of proteoglycans such as heparan 
sulfate [2-4]. 
The first obligate binding event is to CD4, the primary receptor of HIV-1 [5, 6].  
This high-affinity event initiates global rearrangements in the Env trimer spike, exposing 
the coreceptor-binding site, while bringing the virus in closer proximity to the plasma 
membrane [7-9].  Env then binds a coreceptor in a second obligate, high-affinity 
interaction.  The coreceptor, usually a chemokine receptor (CCR5 or CXCR4 or both) 
determines the tropism of the virus (R5, X4, X4R5) and strongly influences the range of 
cells a given isolate may infect [10-14]. 
Receptor- and coreceptor-binding drive further rearrangements in the Env trimer 
that lead to insertion of the fusion peptide into the target membrane, resulting in fusion of 
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the viral and target cell membranes [15-17].   The consequence of this type I fusion 
process is the delivery of the viral core (capsid, RNA genome, and associated enzymes) 
into the cytoplasm of the cell. 
Reverse transcription.    The defining characteristics of retroviruses are the 
reverse transcription of a single-stranded RNA genome into a double-stranded DNA and 
the subsequent integration of that DNA into the host chromatin.  Following delivery of 
the viral core to the cytoplasm are the closely coupled processes of reverse transcription 
and uncoating.  The viral polymerase, reverse transcriptase (RT) starts to transcribe prior 
to uncoating, which is the disassembly of the conical capsid structure and the separation 
of the majority of capsid (CA) from the genome.  But continuation and completion of 
reverse transcription requires uncoating and formation of the reverse transcriptase 
complex (RTC) [18, 19].  Reverse transcription begins by priming off of a Lys3-tRNA 
from a site immediately downstream of the 5’ long terminal repeat (LTR).  This produces 
a script that primes the 3’ LTR to create a negative DNA transcript.  The separate RNase 
H function of RT digests RNA from the RNA:DNA duplex.  Priming of the positive 
strand is provided by an RNase H resistant element of the genome immediately upstream 
of the 3’ LTR.  The fragment protected by this undigested remnant primes on the 
negative strand 5’ LTR, and is extended by the RT as DNA to create a positive strand 
LTR script, which then primes on the 5’ LTR and is extended to give a complete positive 
strand [20, 21]. 
Nuclear import.   At the end of reverse transcription, the 3’ ends of the double 
stranded viral DNA are processed by integrase (IN).  The RTC continues to lose CA as it 
matures into the pre-integration complex (PIC), which must reach the chromatin for 
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integration to occur.  Retroviral PICs actively traffic to the nuclear periphery along the 
microtubules [22].  The PIC is larger than the nuclear pore, and is far too large for 
passive diffusion across the nuclear envelope.  Many simpler retroviruses only efficiently 
infect dividing cells, using breakdown of the nuclear envelope during mitosis to access 
the host DNA [23].  However lentiviruses such as HIV-1 are able to efficiently infect 
non-dividing cells, and must therefore actively transport into the nucleus [24, 25].  The 
details of this process are not known, but interactions between CA and nuclear import 
factors are necessary for import to occur [26]. 
Integration.  Inside the nucleus, integrase interacts with the host protein 
LEDGF/p75, which serves to tether the PIC to the host genome [27, 28].  This interaction 
influences target selection, with HIV-1 showing a strong preference for integration into 
active transcription units [29].  The recessed 3’ hydroxyls, processed by IN in the 
cytoplasm, are then used by IN to attack the phosphodiester backbone at the site of 
integration in a process referred to as DNA strand transfer [30].  The final step in 
integration, gap repair, requires three enzymatic activities, most likely performed by host 
enzymes: a flap endonuclease such as flap endonuclease-1 must trim the 5’-overhangs of 
two mismatched bases; a polymerase is required to fill in the gap; and a host DNA ligase 
must close the single strand nick [31-33]. 
Early and late gene expression.  Once integrated, transcription begins from the 
5’ LTR, which functions as a promoter [34].  The transcription products are spliced to 
produce mRNAs expressing the early genes tat, rev, and nef. Expression of later products 
depends on the accumulation of Tat and especially Rev [35, 36].  Rev binds to a unique 
regulatory sequence, the Rev Response Element (RRE) within the env gene, to promote 
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export of longer, unspliced, or partially spliced transcripts from the nucleus [37, 38].  
Location of these transcripts in the cytosol allows for the expression of late genes, 
including the structural genes gag, gag-pol, and env.  A full length, unspliced 9 kb 
primary transcript is packaged unmodified as the viral genome [39]. 
Assembly and budding.  Virion assembly at the plasma membrane is mediated 
by the major structural protein gag, which brings together two copies of vRNA with its 
tRNALys3 primer, Env, and the enzymes RT, IN, and Protease (PR).  Membrane bound 
gag and gag-pol assembles at a 20:1 ratio into immature spherical particles [40, 41].  The 
amino-terminal matrix (MA) domain is membrane bound via its myristoylation, which 
fixes the site of assembly at the plasma membrane and promotes Env association [42, 43].  
A middle capsid (CA) domain mediates assembly and is the physical component of the 
mature core [44].  The nucleocapsid (NC) domain binds nucleic-acids via its zinc-finger 
motif, and directs incorporation of two copies of the genome into assembling virions 
[45].  The carboxy-terminal p6 region contains the so-called “late domain” which 
engages components of the ESCRT pathway critical to pinching off the membrane from 
the cell thereby completing the assembly process [46]. 
Due to a -1 frameshift at the end of gag, a fraction of the incorporated Gag is 
expressed as a longer product, Gag-Pol, containing the PR, RT, and IN domains.  During 
and immediately following the budding event, PR cleaves the immature polyprotein into 
the protein products MA, CA, NC, p6, PR, RT, and IN.  CA, separated from the 
membrane bound MA, reassembles into the conical shape of the mature core [47]. 
 
6	  
 
1. B.  THE ENVELOPE GLYCOPROTEIN 
Env Glycoprotein Assembly and Structure 
Env trimer maturation.  The HIV-1 Env, like all type I viral fusion proteins, has 
a trimeric quaternary structure.  Env is synthesized as a single polypeptide, gp160, of 
approximately 850 amino acids, with an amino-terminal signal peptide that targets it co-
translationally to the ER.  In the ER, gp160 is heavily glycosylated, acquiring N-linked 
sugars on approximately 27 residues [48, 49].  Signal peptide cleavage is delayed, and 
passage of gp160 through the ER is slow, allowing for extensive isomerization of its 10 
disulfide bonds [50-52].  Folded gp160 organizes into trimers and is transported into the 
Golgi apparatus, where it is cleaved by furin-like proteases into two fragments, the 
surface subunit gp120 and the transmembrane subunit gp41 [53-55], which remain non-
covalently associated [56].  The surface gp120 subunit contains the receptor and 
coreceptor-binding sites, is highly glycosylated, and contains a number of highly variable 
regions [48, 57].   The transmembrane subunit, gp41, consists of a hydrophobic fusion 
peptide (FP) region, two heptad-repeat regions named NHR and CHR (also known as 
HR1 and HR2), a membrane proximal ectodomain region (MPER), a membrane-
spanning domain, and a carboxyl terminal endodomain.  Maturation of the Env by 
protease cleavage increases the conformational freedom of gp120, critical for fusion and 
immune evasion [58]. 
Ectodomain structure.  The gp120 monomer is conventionally divided into five 
constant and five variable regions [59].  The constant regions of gp120 fold into a 
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conserved core structure, with the variable regions forming looped extensions from this 
core [57].  The conserved gp120 core consists of an inner domain that interacts with the 
gp41 stalk, a heavily glycosylated outer domain, and a bridging sheet minidomain that 
connects the two.  The bridging sheet consists of four antiparallel β-strands, two from the 
V1/V2 stem in the inner domain and two from the outer domain.  The bridging sheet and 
neighboring V3 stem contain residues of the coreceptor-binding site [57, 60-62].   
Gp120 contains conformationally variant and invariant regions.  The inner 
domain is structured as a 7-stranded β-sandwich from which emanate three loop 
‘excursions’ and the N- and C-termini. (See Fig. 1.1)  The β-sandwich, together with the 
N- and C-termini, form a gp41-interacting region.  The loop excursions emanating from 
the β-sandwich form three stacked layers containing α-helical structure.  The outer 
domain is an extension of the third topological layer.  The outer layer and the inner β-
sandwich are conformationally stable between liganded- and unliganded-states, with 
three inner domain layers being much more conformationally dynamic [63-65].  The 
topological layer model, based on crystal structures of the gp120 core bound to various 
ligands, is supported by hydrogen deuterium exchange (HDX) studies of bound and 
unbound gp120 core [66], as well as full length glycosylated gp120 [65].  Upon CD4 
binding, the mobile inner domain layers all slow their rate of HDX, indicating a decrease 
in structural flexibility.  The change is most dramatic for topological layer 2, in the 
bridging sheet residues, and in the helix immediately N-terminal to the sheet.  For the 
outer domain, which has a net lower rate of exchange, decreases are seen only in the 
bridging sheet residues and in the CD4-binding loop [65]. 
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The Consequences of Receptor Binding 
CD4 binding induces changes in the gp120 tertiary structure. Entry begins 
with CD4 attachment to the CD4-binding site (CD4bs) on gp120 located within the cleft 
of the trimer.  CD4 binds a large hydrophobic cavity in gp120 between the inner, outer 
and bridging sheet domains, with the cavity being capped and partially occupied by a 
Figure 1.1.  The domain structure of core gp120. Cartoon representation of CD4/48d-bound gp120 
core with extended termini PDB: 3JWD after Pancera et al. [63].  The gp41 interacting domain is 
composed of N- and C-termini (green) and 7-stranded β-sandwich (red). The inner domain mobile 
layers 1-3 are represented in purple, cyan, and blue, respectively. The outer domain is represented in 
orange.  Figure generated in PyMol. 
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critical phenylalanine (Phe43) of CD4 [67, 68].  Comparison of liganded and unliganded 
SIV gp120 structures initially indicated that the bridging sheet structure was only formed 
upon CD4 binding [68].  Furthermore, the crystal structures of core gp120 bound to 
several antibodies revealed conformations in which the bridging sheet was not formed 
[69, 70].  However, these observations are not in good agreement with the available cryo-
EM data for trimeric Env [71, 72].  Moreover, an “extended core” of gp120, containing 
more of the V3 and an intact N terminus, has now been crystallized in unliganded and 
liganded states with the unliganded extended core forming a structure very similar to that 
of the CD4-liganded state.  Biochemical analyses favor a model in which the CD4-
liganded state is a ground state, and the unliganded gp120 is discouraged from sampling 
this state by the V1/V2 and V3 regions [73].  
 CD4 binding induces changes in the Env trimer quaternary structure.  In 
addition to the changes in tertiary structure of the gp120 monomer induced by CD4 
binding, there are distinct changes in the quaternary structure of the Env trimer that 
expose the coreceptor-binding site.  Cryo-electron tomography has been used to visualize 
the Env trimers in liganded and unliganded states.  CD4 binding corresponds to a rotation 
of the monomer away from the central axis of the trimer.  This rotation moves the trimer 
from a “closed” to an “open” conformation in which the V3 stem and associated 
coreceptor-binding site are located at the apex of the spike, making them accessible for 
binding to a coreceptor in the target membrane [71, 74]. 
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Figure 1.2.  A model of HIV-1 entry. gp120 subunits are represented with schema of topological 
layers.  The outer domain is represented in orange.  The inner domain layers one, two, and three shown 
in purple, cyan, and blue, respectively.  The invariant β-sandwich (red) is shown with N- and C-termini 
(green) emerging at the interface with gp41.  The gp41 subunit is shown with fusion peptide as a dark 
green line attached to the N-terminal Helix Region (NHR) in light green, the C-terminal Helix Region 
(CHR) in light purple, and the transmembrane and endodomain are represented as a dark purple line. 
CD4 is shown with its four Immunoglobulin domains in gray, and the seven transmembrane domain 
receptor CCR5 is represented in black, with red stars representing site of tyrosine sulfations.  A, Prior to 
CD4 binding, V1/V2 (light blue loops) and V3 (black loop) hold Env in a closed conformation.  B, 
After binding CD4 and CCR5, the bridging sheet forms between the V1/V2 stem and beta-20-21 
hairpin (orange line) of the outer domain.  CCR5 binds at the bridging sheet with tyrosine sulfated N-
terminus binding at the base of the V3. C, Following receptor and co-receptor binding, the gp41 fusion 
peptide is inserted into the target cell membrane forming the Pre-Hairpin Intermediate (PHI).  D, The 
viral and cellular membranes fuse, and the six-helix bundle forms with the CHRs packs into grooves 
formed by the interior bundle of NHRs. 
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CD4 binding to gp120 is an entropically unfavorable process. CD4-gp120 
binding is notable as an extreme example of an enthalpy driven process.  There is a high 
entropy cost to CD4-gp120 binding that is compensated for by gains in enthalpy [75].  
The large negative entropy change appears to be due to loss of sampling of alternative 
structures rather than folding of unstructured polypeptide [66, 73].  CD4 binding imposes 
direct constraints on layers 2, 3 and the outer domain, fixing their orientation and 
decreasing conformational mobility.  The consequence of the high entropic barrier is a 
“conformational masking” of the CD4-binding site epitope [67].  Thus conserved 
conformations are masked from antibody recognition by the high energy barrier, ensuring 
that the antibodies that emerge early in infection will be to non-conserved epitopes, 
which do not require the fixing of mobile topological layers for recognition. 
CD4 binding exposes the coreceptor-binding site.  The major HIV-1 
coreceptors are the chemokine receptors CCR5 and CXCR4.  Both are seven-pass 
integral membrane proteins with long free N-termini containing sulfated tyrosines [76, 
77].  Binding of R5 tropic isolates in particular is dependant on the strongly 
electronegative sulfotyrosines in the N-terminus, which bind to pockets at the base of the 
V3 loop [62].  Receptor and coreceptor binding to the Env glycoprotein are not strictly 
serial, as they are mutually reinforcing and cooperative events [75, 78].  Binding of CD4 
or of the coreceptor proxy 17b Ab leads to an opening of the Env trimer conformation 
[74].  Access to the coreceptor-binding site is limited by V1/V2 [79, 80], and elimination 
of these regions confers a degree of CD4 independence to Env [81].  Masking of the 
coreceptor-binding site prior to CD4 engagement serves to limit exposure to neutralizing 
antibodies until the target membrane is close enough to limit access to this site [82]. 
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Changes in gp41 due to CD4 binding.  The conformational changes that take 
place in gp120 upon receptor and coreceptor binding lessen the association with gp41, 
and in some lab adapted strains the ectodomain is “shed” when exposed to soluble CD4 
[83].  At the same time, structural rearrangements in gp41 are initiated, leading ultimately 
to membrane fusion by a mechanism conserved among all type I viral fusion proteins [16, 
17].  The N-terminus of gp41 contains a hydrophobic fusion peptide, which is 
sequestered in the center of the trimer.  Engagement with receptor and coreceptor leads to 
extension of the N-terminal fusion peptide away from the virus and into the target cellular 
membrane.  This extended structure is referred to as the pre-hairpin intermediate (PHI), 
and this state persists long enough to be a target of fusion inhibitors [84-87]. 
Formation of the six-helix bundle.  The energy that drives viral fusion is 
generated by the rearrangement of the metastable PHI into a six-helix bundle.  Between 
the fusion peptide, now in the cellular membrane, and the transmembrane of gp41, there 
are two regions of repeating amphiphilic heptads.  The amino-terminal heptad repeat 
(NHR) is next to the fusion peptide, and the carboxy-terminal heptad repeat (CHR) is 
near the transmembrane region, with the two regions linked by a disulfide containing 
“immunodominant region”, so called because of its high immunogenicity.  Arranged in a 
trimer, the NHRs form a bundle with three hydrophobic grooves.  When the PHI 
collapses into the six-helix bundle, the CHR fill these grooves, a conformation described 
as the trimer of hairpins [15, 88].  The formation of this highly stable structure brings the 
viral and plasma membrane into close proximity, promoting lipid mixing and viral fusion 
[16, 89]. 
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1. C.  PEPTIDE AND PROTEIN INHIBITORS OF HIV-1 ENTRY 
HIV-1 Neutralizing Antibodies 
The Three Faces of Env.  A lentiviral infection can persist for years before 
killing its host, requiring the virus to be exposed to the host immune system for a long 
period of time.  The complexity and variability of the HIV-1 envelope glycoprotein is 
driven in part by the need to evade immune recognition. In the early stages of infection, 
the first Env specific antibodies to appear are non-neutralizing antibodies recognizing 
gp41 [90].  Non-neutralizing antibodies that recognize gp120 emerge over the next few 
weeks, with neutralizing antibodies (NAbs) emerging months after primary infection.  
These early emergent NAbs are narrowly neutralizing, and do not recognize heterologous 
viruses [91-93].  Such autologous neutralizing antibodies are raised against regions of 
high variability in gp120, such as the V1/V2, and the V3 regions [92, 94, 95].  Broadly 
neutralizing antibodies (bNAbs) emerge after years of persistent infection [96-98]. 
 A large number of Env antibodies have been isolated from HIV-1 patient B-cell 
repertoires, have been characterized, and have served as tools for probing Env structure 
and function.  Prior to the availability of a crystal structure, gp120 was mapped using 
gp120 mutants together with antibody binding and competition assays.  Antibodies 
against gp120 were classified by whether they competed with sCD4 for binding, whether 
their epitopes were inducible, whether they neutralized, and the location of the mutations 
that abrogated their binding [99].  These techniques allowed for the mapping of 
neutralizing and non-neutralizing antibodies to theoretical surfaces of gp120 [100].  
Neutralizing and non-neutralizing faces were identified, distinguishing between epitopes 
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that are exposed or concealed in the intact trimer [101].  With the availability of a gp120 
core crystal structure, a third face was identified.  This is termed the “silent” face, due to 
the scarcity of antibody epitopes in this region, and it corresponds to that part of gp120 
concealed beneath the so-called glycan shield [57, 60].   The subset of antibodies that are 
broadly neutralizing (bNAbs) has been especially well studied.  They are potentially 
useful as inhibitors in their own right, and represent the subset that one would want to 
elicit with a vaccine.  In addition, they highlight the vulnerabilities of HIV-1 helpful in 
the design of inhibitors of HIV-1 entry. 
 
bNAbs Recognizing the Receptor-Binding Sites 
CD4-binding site antibodies.  For antibodies to be neutralizing, they must have 
access to their epitopes, either in the unliganded state, or transiently during the entry 
process.  For an antibody to be broadly neutralizing, its epitope should be conserved.  
Among the most conserved epitopes are those of the receptor-binding sites.  Functional 
requirements restrict the variability of the CD4-binding site (CD4bs), and ensure it is 
accessible.  HIV-1 limits neutralization at the CD4bs through steric hindrance and 
conformational masking.  The site is recessed in the trimer cleft and is protected by a 
glycan shield, thus limiting access to the site by molecules larger than the first 
immunoglobulin domain of CD4.  Conformational masking refers to the high entropy 
barrier to fixation of this epitope [67]. 
The first well-characterized CD4bs antibody was b12 [102], which has a 
neutralization breadth of approximately 40-50% [103, 104].  Neutralization breadth is 
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commonly defined as the percentage of Env isolates that are neutralized to a 50% 
inhibitory concentration (IC50) by a concentration of 50 µg/mL across a wide array of 
isolates with the results obtained being dependant on the composition of the panel used.  
The b12 antibody binds with a lower entropic penalty than CD4 but also with a lower 
enthalpy gain [67].  Binding of CD4 imposes constraints on layers 2, 3 and the outer 
domain.  In contrast, b12 binding constrains only layer 3 and the outer domain, leaving 
layer 2 of the inner domain, which contains the V1/V2 stem, unconstrained [63, 70].  The 
CDRL3 of b12 places a tyrosine in the Phe43 cavity of the CD4-binding site, while the 
CDRH3 contacts with the beta20-beta21 strands that are the outer domain contributions 
to the bridging sheet.  Thus b12 overlaps with the coreceptor-binding site, without 
stabilizing the bridging sheet contact between layer 2 and the outer domain.  With fewer 
constraints placed on binding, one would expect that a greater number of conformational 
states would be able to bind b12.  This has been probed using cross-linking studies.  
Glutaraldehyde cross-linking was used to freeze the envelope glycoprotein in a mixture 
of states, and ligands were evaluated for binding to cross-linked and untreated gp120.  
Relative binding ratios of cross-linked to untreated gp120 were presumed to reflect the 
proportional occupancy of states that the ligand can bind.  From these studies it was 
observed that sCD4 binding was much more restricted by cross-linking than was b12 
[73].  Perhaps as a consequence of the divergence of the b12 epitope from the CD4bs, 
this antibody as mentioned lacks breadth.  This lower breadth suggests that the barrier to 
escape from this antibody is low.  Some of the limitations on the breadth of b12 may also 
be a consequence of quaternary limitations.  Residues that impact gp120 binding have 
been identified, but these do not directly correlate with neutralization.  Rather isolates 
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known to have a more open conformation in the trimer are typically more neutralization 
sensitive [105].  Binding of b12 to trimer requires an induction of a quaternary shift that 
may reflect steric restraints on its binding [71, 74, 106]. 
A number of much more broadly neutralizing (~90% of isolates tested to IC50 at 
50 µg/mL) CD4bs antibodies have recently been identified, such as VRC01, 3BNC117, 
and NIH45-46 [103, 107].  The best studied of these is VRC01, which has a 
neutralization breadth of 91% compared to 41% for b12 in the same study.  VRC01 binds 
residues that closely match CD4 contacts.  Interactions are almost entirely mediated by 
the heavy chain, and VRC01 light chain contains an unusual deletion of two amino acids 
in the CDRL1 that reduces a steric clash with Loop D of gp120 [108].  VRC01 binding to 
monomeric gp120 has a similar thermodynamic profile to that of CD4/gp120 binding, 
with high entropic cost and a high enthalpic pay-off.  As with CD4/gp120 binding, the 
entropic penalty of VRC01/gp120 binding partially lowers the entropic barrier to binding 
for coreceptor-binding site antibody 17b, and these antibodies bind cooperatively to 
gp120 [103, 109, 110].  However, VRC01 is not a perfect proxy for CD4.  In cross-
linking experiments VRC01 behaves more like b12, binding a larger proportion of locked 
conformers than sCD4 [73].  Cryo-EM studies of the Env trimer bound to VRC01 and 
17b shows an interesting pattern of quaternary structures.  When mixtures of VRC01 and 
17b are bound to trimer, two populations are observed: a closed conformation with 
VRC01 bound, resembling the unliganded trimer, and an open conformation with bound 
17b, resembling the CD4-liganded trimer.  The suggested model is that when VRC01 
binds to Env, it locks in a closed conformation which prevents 17b binding, but if 17b is 
prebound, locking in the open conformation, VRC01 will still bind that open 
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conformation [74].  The conformational promiscuity of VRC01 binding suggests a partial 
explanation for its great breadth. 
CD4 induced antibodies.  Like the CD4-binding site, the coreceptor-binding site, 
located at the bridging sheet and the V3 base, is constrained by functional requirements, 
and residues within this site are among the most conserved on gp120 [111].  Unlike the 
CD4-binding site, the coreceptor-binding site does not need to be accessible in the 
unliganded state, and access to this site is limited prior to CD4 binding.  Antibodies that 
bind CD4 induced epitopes in this region (CD4i antibodies) are believed to bind like the 
coreceptor, and their binding has been used to make inferences about the nature of the 
structural transitions that take place during entry.  The prototypical CD4i antibody is 17b, 
which binds the bridging sheet.  Like CD4-binding, the binding of 17b to gp120 incurs a 
high entropic penalty; however, when CD4 is prebound, the entropic penalty of binding 
17b has already been paid [109].  Consideration of the 17b binding surface on gp120 
provides insight into this entropic barrier: 17b binding to the bridging sheet fixes inner 
domain layer 2 to the outer domain, thus restraining inner domain layer 3 and locking 
gp120 in the CD4-liganded conformation [57].   
Access to the coreceptor-binding site is restricted by the V1/V2.  Deletion of the 
V1/V2 region allows for binding of CD4i antibodies to the gp120 monomer and can 
render HIV-1 somewhat CD4 independent [81].  Additionally, there are steric restrictions 
on access to the coreceptor-binding site in the context of the trimer.  CD4i antibodies can 
bind to unliganded trimer in lab-adapted isolates, which are known to assume an open 
conformation, but are limited in their ability to bind primary isolates [82].  By cryo-EM, 
17b is only observed bound to the open conformation [74].  CD4i antibodies are poor 
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neutralizers of primary isolates despite their ability to bind sCD4-induced trimers.  
Inefficient neutralization by these antibodies may be attributed to the temporal and steric 
restrictions on access to their epitope.  The CD4i epitope is unmasked only in the window 
of time between receptor binding and coreceptor binding.  However, at this time, the 
virus is in close proximity to the cellular membrane, which sterically limits antibody 
access.  Consistent with this, and unusually for HIV-1 neutralizing antibodies, the 
monovalent Fab forms of these antibodies are more active than the larger divalent IgG 
forms.  Antibody addition experiments show that this difference is attributable to their 
differing ability to bind Env after receptor engagement [82].  There may therefore be less 
selective pressure at the coreceptor-binding site, explaining its conservation, and 
suggesting it would make a good target for inhibitors small enough to access this site. 
The N-terminus of the HIV-1 coreceptor CCR5 contains several sulfotyrosines 
critical to Env binding, and the ability to bind sulfotyrosines is retained even in X4 tropic 
viruses [78, 112].  A number of CD4i antibodies contain long flexible CDRH3s rich in 
acidic residues and tyrosines, which promotes their sulfation [113].  These antibodies 
bind the sulfotyrosine binding pockets at the base of the V3 loop, which is part of the 
coreceptor-binding site [62, 114, 115].  The CDRH3 of 412d contains two sulfated 
tyrosines, and has been crystallized bound to gp120. The gp120/412d co-crystal reveals 
two sulfotyrosine binding pockets at the base of the V3 and shows that, as with 17b, the 
bridging sheet is fixed [62].  A similar pattern with glutaraldehyde fixation is observed 
for 412d as for 17b, suggesting that the conformational masking evident in the isothermal 
titration calorimetry (ITC) measurements of 17b binding to the bridging sheet would hold 
for binding to the sulfotyrosine binding pockets [73].  A related antibody E51, from the 
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same VDJ recombination event in the same patient, has an even longer CDRH3, and like 
the N-terminus of CCR5, contains four potentially sulfated tyrosines [112, 114].  It is this 
CDRH3 that is the starting point for the CCR5 mimetic peptide that participates in the 
double mimetic we generate and characterize in Chapter 4.  
 
bNAbs Recognizing Non-Binding Site Epitopes 
Antibodies recognizing gp120 glycosylations.  Aside from antibodies 
recognizing the receptor- and coreceptor-binding sites, there are several classes of bNAbs 
targeting other Env glycoprotein epitopes [116].  N-glycosylations can form and 
contribute to these additional epitopes, partially and wholly [117].  It is somewhat 
counterintuitive that one would find bNAbs dependent on glycosylations: protein-glycan 
interactions are relatively weak, anti-glycosylation antibodies tend to be autoreactive, and 
most glycosylation sites are poorly conserved [116, 118].  However, some of these 
glycosylation sites can be relatively conserved due to their role in protein folding, and 
these conserved glycans participate in a number of bNAbs. 
Moreover, the density of glycosylation sites on gp120 is itself a distinctive 
feature, and this density results in less efficient trimming of mannose residues during 
processing in the ER and Golgi [119, 120].  An epitope containing multiple such residues 
can be recognized as non-self.  A well-characterized antibody of this type is 2G12, which 
recognizes high mannose type glycosylations in the conserved regions at the base of the 
V3 loop, and within the V4 loop [99, 121].  2G12 has a unique domain swap structure, 
where the VH domains of the two Fabs of the IgG dimer cross-pair with the opposite VL 
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domains.  This unique domain structure brings the binding sites of the two Fab arms into 
close proximity, allowing for recognition of the multivalent epitope provided by the 
clustered glycosylations [122].  Although the 2G12 epitope is not itself critical to Env 
function, this antibody appears to neutralize by blocking access to the coreceptor-binding 
site [123].  
A different set of N-glycan dependent antibodies is that represented by the bNAbs 
PG9 and PG16.  These antibodies reach through the glycan shield to recognize an epitope 
made of two N-glycosylations and a stretch of peptide in the V1/V2 region of gp120 
[124, 125].  The epitope for PG9 contains elements from more than one unit in a trimer, 
giving this antibody the unusual characteristic of efficiently recognizing native trimer 
while poorly binding the gp120 monomer [126].  Binding of a single antibody to one 
monomer of a trimer blocks CD4 binding to all monomers [127].  
MPER antibodies.  Unlike gp120, gp41 is relatively inaccessible, and anti-gp41 
antibodies are mostly non-neutralizing.  An exception to this rule is the class of 
antibodies recognizing the membrane-proximal external region (MPER), an induced 
epitope that, for many isolates, is only accessible during entry for many isolates [128, 
129].  The MPER is a stretch of gp41 that inflects to rest along the lipid surface before 
traversing the membrane; a structure that has been described as the “knee” of gp41.  Two 
of the anti MPER antibodies so far identified, 4E10 and 2F5, have long hydrophobic 
CDRH3s that bind phospholipids, which may increase their concentration at the 
membrane during the exposure of this epitope [130, 131].  A third such antibody, 10E8, 
recognizes an epitope shifted several residues from the membrane, and does not bind 
lipids [132].  MPER antibodies do not appear to account for a major component of the 
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neutralizing antibodies elicited in the course of infection [116].  These antibodies tend to 
be autoreactive, which may account for their scarcity [133, 134].   
 
Peptide inhibitors of HIV-1 Entry 
Peptide inhibitors of HIV-1 replication.  The exposure of the envelope 
glycoprotein to the extracellular milieu makes it vulnerable not only to antibodies, but 
also to peptide inhibitors.  Peptide inhibitors, like antibodies, face the same set of 
challenges in neutralizing a highly variable target.  Although compared with antibodies 
peptides suffer from poor bioavailability, they are synthesizable and can potentially reach 
targets that are inaccessible to antibodies.  Like antibodies, peptides can be expressed in 
biological systems, and improved through display technologies. 
A CD4-mimetic peptide constructed by loop grafting.  The CD4-binding site 
on gp120 contains a hydrophobic pocket critical to binding.  This pocket fits the Phe43 
residue on CD4, which resides on a highly surface exposed β-turn [57].  This end of this 
β-turn in CD4, contained in residues 40-48, is responsible for 63% of the contact area.  
The Phe43 alone provides 23% of this contact area [57].  However, linear peptides from 
this region fail to inhibit HIV-1 entry, presumably due to a lack of secondary structure, 
and the extra entropy cost associated with folding a disordered peptide [135].  Attempts 
to enforce a β-hairpin through disulfide cyclization [136], or in a synthetic cyclized 
peptidomimetic failed to produce significant specific binding activity [137].  The 
laboratory of Claudio Vita solved this problem by grafting the residues 40-43 (QGSF) 
onto the β-hairpin of a scorpion-toxin scaffold [138].  
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Scorpion toxin consists of an N-terminal α-helix stapled to a C-terminal β-turn by 
three disulfide bonds.  This fold tolerates substitutions in the α-helix or the β-turn, and 
even the deletion of a disulfide bond [139-141].  A large number of these toxins are 
observed in nature, and there is no sequence conservation other than the disulfide bonds 
[142].  This scaffold has been used to present α-helix derived from an anti-fibrinogen 
antibody [139], and to engineer a metal-binding motif in the β-turn of the scaffold [140]. 
Following the successful grafting of the Phe43 loop onto the scaffold, a 
combinatorial approach was used to optimize and obtain a high affinity, semi-synthetic 
peptide using non-natural amino acids [143].  Significantly this peptide was shown to 
induce the CD4i epitope of the coreceptor-binding site antibody 17b [144, 145].  This 
peptide has been co-crystallized with gp120 and 17b, and its binding induces the same 
conformation as does CD4 [57, 146].  This is in contrast to the structures of the CD4bs 
antibodies b12, b13, and F105 [69, 70]. 
Coreceptor-mimetic peptides.  High affinity binding of HIV-1 Env to the 
coreceptor CCR5 is dependant on the sulfation of CCR5s N-terminal tyrosines, and a 
number of antibodies to the coreceptor-binding site on gp120 contain sulfated tyrosines in 
their CDRH3s [114].  Sulfated peptides based on the N-terminus of CCR5 or on the 
CDRH3s of CD4i antibodies can be used to inhibit HIV-1 entry [112, 147].  The 
sequences of the CCR5 N-terminus and the CDRH3s of E51 and 412d may be aligned by 
their tyrosine patterns; the 412d peptide can be swapped in for the N-terminus of CCR5 
to generate a coreceptor capable of supporting infection by R5 tropic virus [115].  The 
strength of this interaction derives from the negatively charged sulfates interacting with 
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positive residues in the binding pockets at the base of the V3, while aliphatic residues that 
line the pockets interact with the aromatic ring of the tyrosines [62].  The strength of 
these electrostatic contacts is sufficient such that the exact secondary structure of the 
peptide backbone is less constrained.  The crystal of the unbound E51 does not resolve 
discernable structure in the CDRH3, implying this loop is relatively unconstrained.  As 
such, the free peptides derived from the CDRH3 or the N-terminal fragment from CCR5 
can bind without a scaffold anchor.  Indeed, a short highly sulfated peptide derived from 
the CDRH3 of CD4i antibody E51, and improved through mutagenesis, is the strongest 
coreceptor mimetic yet identified [112, 148]. 
Fusion inhibitors.  Following receptor and coreceptor binding, gp41 extends and 
inserts its N-terminal fusion peptide into the target membrane, forming a high-energy 
state pre-hairpin intermediate.  Subsequently this intermediate collapses into a six-helix 
bundle, driving fusion of the two membranes. This six-helix bundle is formed by two 
heptad repeat sequences in the N- and C-terminal regions of the gp41 ectodomain (NHR 
and CHR) [149].  In the six-helix bundle, the NHR segments from three gp41 
ectodomains form a central trimeric coiled-coil, defining three hydrophobic grooves.  
Folding over to form a hairpin, the CHR helices pack into these grooves in an antiparallel 
fashion [15, 88, 150].  In the prehairpin extended conformation, the NHR and CHR 
segments are not yet associated and are transiently accessible to fusion inhibitors.   
Inhibitors based on segments of the CHR are called C-peptides and work by packing into 
the central hydrophobic grooves in place of the CHR [87, 151]. One such peptide, T20 
(Fuzeon, enfuvirtide) has been approved for use in HIV-1 infected individuals as a 
salvage therapy.  Escape mutants to this peptide readily emerged, some of which work by 
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increasing the kinetics of fusion to decrease the availability of the pre-hairpin 
intermediate target [152]. 
 
1. D.  PHAGE DISPLAY AND RELATED TECHNOLOGIES 
Phage display and maturation of protein ligands 
The phage display technique.  Phage display of proteins is a conceptually 
simple, yet powerful technique to connect a protein of interest (POI) to the genomic 
material that encodes it.  This allows for the selection of genomic material based on the 
binding properties of its product.  Filamentous phage were among the first commonly 
used cloning vehicles [153-155], and some of the features that made them attractive tools 
for molecular cloning also make them attractive as a display technology.  The genome is 
small (6.4 kb), yet is able to tolerate insertions into the major intergenic region, which 
can more than double its size.  It is non-lysogenic, greatly simplifying its handling, and 
allowing it to persist in culture.  Both of these qualities derive from the processive 
extrusion process by which new virions are produced.  Once packaging has begun at the 
morphogenic (packaging) signal, the phage will continue to ratchet the genome through 
the inner membrane, assemble in periplasm, and extrude the nascent filament through a 
pore in the outer-membrane until the end of the genome is reached.  This obviates the 
need for membrane lysis and also means that the capsid contains no intrinsic 
determinants of length or content [156]. 
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Polyvalent Display.  The pIII minor coat protein of filamentous phage serves two 
distinct functions in the viral life cycle. The C-terminal domain, connected to the tip of 
the phage, is responsible for liberating the phage from the host at the end of the assembly 
process.  The two N-terminal domains (N1 and N2) mediate receptor binding and entry 
into a target cell.  N2 engages the primary receptor at the tip of the pilus.  The pilus 
retracts bringing N1 into proximity with the coreceptor, the membrane protein tolA, to 
initiate entry of the genome into the target cell [157].  Importantly, these domains are 
modular, connected to each other by long flexible linkers of exceptional regularity 
([EG3S]3EG3 and [G3S]3[EG3S]4G3SGSG) and have been likened to beads on a string.  
Phage display with replication competent phage (e.g. fd-tet) is achieved by merely adding 
another bead to the N-terminus of the string [158, 159].  However, the large size of these 
vectors, and the fact that the inserted protein can interfere with replication, limits the 
utility of replication competent systems [160, 161].  Furthermore, replication competent 
vectors are inherently polyvalent: all of the 3-5 copies of the minor coat protein will be 
fusions to the protein of interest, which introduces the potential for multipoint attachment 
and undesirable avidity effects. These problems were addressed by the development of 
phagemid display vectors [162]. 
Phagemid vectors.  A phagemid is a pBR322-derived plasmid to which a phage 
origin of replication has been added.  The phage ori is the start site of single strand 
synthesis and the morphogenic (packaging) signal.  These elements are sufficient to 
ensure that any circular DNA construct containing the ori in the context of replicating 
phage will be packaged as single-stranded DNA (ssDNA).  The combination of a phage 
ori with an unconstrained pUC origin was found to generate dominant defective 
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interfering particles.  In the host bacterium, filamentous phage go through a double-
stranded stage, the replicative form (RF).  The unconstrained plasmid origin causes this 
form to be amplified, which then ensures that the majority of the circular ssDNA scripts 
generated upon rescue with helper phage will be phagemid in origin. 
This interference is caused by the amplification of the double stranded RF 
provided by the plasmid origin, which ensures that the majority of circular ssDNA forms 
available for packaging were from that source, swamping the genomes of replication 
competent phage [156].  This has been widely used to generate large quantities of ssDNA 
for molecular biological applications such as Kunkel mutagenesis.   
Monovalent display.  A phagemid display vector also encodes a coat protein 
fused to the POI.   Since the replication competent helper phage supplies a fully 
functional copy of pIII, the protein of interest can replace the N-terminal domains of the 
phagemid encoded pIII, with the C-terminal domain ensuring incorporation into phage 
particles [162].  The valency of display is then controlled by use of an inducible Lac 
promoter.  In the absence of induction, low expression of the POI-pIII fusion ensures that 
most particles will have only the wild type pIII and a small minority will have only one 
copy of the fusion.  As expression increases, more POI-pIII fusion will be expressed, and 
more particles will have multiple copies of the POI-pIII fusion.  At least one copy of wild 
type pIII must present for the particles to be infectious [162, 163]. 
Phage panning.  Panning is the selective enrichment of phage particles with the 
desired binding characteristics.  Panning can be solution-phase or solid-phase.  The most 
basic form of solid phase panning involves adherence of the bait protein to the plastic 
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surface of an ELISA plate.  More typically, beads are used as a substrate.  Phage particles 
are allowed to bind to the bait, and then are removed in a series of washes.  Stringency is 
introduced by the wash steps, which select for a slower off-rate.  With solution-phase 
panning, phage and bait are allowed to encounter in solution, and then are coprecipitated 
with beads.  In both cases, following the wash steps, phage are eluted from the substrate 
and amplified, a process that may be repeated several times until the library has been 
reduced to an appropriate size for evaluation. 
 
Other Display Technologies 
 Surface display techniques.  Though phage display is by far the most common 
surface-display technique, there are a number of other technologies used for display, each 
with their own advantages and disadvantages.  Filamentous phage display has a number 
of weaknesses which competing techniques seek to address.  For example, some proteins 
will not express in the periplasm of E. coli or will not express as a fusion to pIII.  Also, 
phage particles are too small to use cell-sorting techniques, which could otherwise be 
used with labeled soluble bait to control for unpredictable valency and undesirable 
avidity effects.  Moreover, some proteins require post-translational modifications, in 
which case no bacterial system will suffice. 
Each alternative system has its own tradeoffs.  The parameters that define the 
utility of these display systems are the complexity of the starting library, the number of 
unique library members that can be evaluated, and the relative ability to distinguish 
between binders of differing affinities.  Different systems will also have different 
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intrinsic limits, such as on the size, hydrophobicity, and modifications of the proteins that 
can be displayed.  Artifacts introduced at the amplification step caused by factors such as 
codon usage, metabolic burden, and toxicity, can confound discrimination between 
library members in ways that differ between systems. 
 Bacterial display.  Use of whole bacterial cells as a display platform allows for a 
great number of protein scaffolds to be used in contrast to phage display which is limited 
to fusion with the phage coat proteins [164].  The limits on library size are similar to 
those for phage display and are dependant on transformation efficiency.  Evaluation of 
library members is by cell-sorting, and the size of the library that can be evaluated is 
subject to the throughput limits of this technique, typically in the range of 107 cells [165].  
Magnetic sorting, with bait protein conjugated to magnetic beads, can be used to consider 
a library of arbitrary size.  However here avidity is a factor so this approach is typically 
used to narrow the size of the library in the initial rounds of selection.  Fine distinctions 
between binders are distinguished through later cell-sorting rounds with limiting amounts 
of fluorescently labeled bait [164-166]. 
Yeast Display.  Display of peptides and proteins on the surface of Saccharomyces 
cerevisiae has been achieved by fusing the POI to the C-terminus of the Aga2p mating 
adhesion receptor. Yeast display allows for the presentation of large proteins, and of 
those that can only fold in a eukaryotic system.  Library complexity is regularly in the 107 
range and has been reported to be as high as 109 members [167]. Many thousands of 
copies of the POI may be displayed on the surface and as with bacterial display, selection 
is typically achieved by cell-sorting on a fluorescently labeled target protein, with similar 
throughput limits to selection in the range of 106-107 individual cells [168], and 
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consideration of larger libraries is accomplished by first selecting with magnetic beads 
before rounds of selection by cell-sorting [167, 169, 170]. An additional advantage for 
library construction for the display of a heterodimeric protein, such as Fabs, is that 
mating can be used to achieve large combinatorial libraries [171, 172].  A limitation of 
yeast display is post-translational modifications are significantly different between yeast 
and mammalian cells. 
Mammalian surface display.  Display of proteins on the surface of mammalian 
cells is a technique analogous to yeast display that allows for native mammalian folding 
and post-translational modifications.  The basic requirements of a mammalian surface 
display vector are a POI expressed as a fusion to a transmembrane domain for cell 
surface presentation, and a means of maintaining POI expression.  One way of achieving 
the latter is by transfection of a vector containing an episomal origin of replication and a 
selectable marker [173, 174].  An example of such a system is the commercially available 
pDisplay vector, which utilizes a PDGFR transmembrane domain, a neomycin-selectable 
marker as well as an SV40 origin for episomal maintenance [175].  Cell number in 
mammalian tissue culture limits library size, typically in the range of 106 cells [176]. 
An alternative system, and one with a means of approximating a single POI per 
cell, is expression of a POI-transmembrane fusion from a lentiviral vector.  Co-
transfection with lentiviral packaging plasmids and an envelope protein is used to 
generate pseudovirus particles, which can then be used at a low multiplicity of infection 
to generate the cell library.  From this point on the system is treated the same as an 
episomal system and is subjected to successive rounds of passage followed by selection 
[177].   
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As with yeast display, in mammalian cell-surface display selection is typically 
achieved with cell-sorting on a fluorescently labeled soluble target, so that target avidity 
is not an issue.  Here again, initial rounds of selection may be performed with magnetic 
beads to consider an arbitrarily large library size.  An interesting feature of mammalian 
display is the possibility of utilizing the somatic hypermutation pathway to introduce 
diversity into antibody libraries.  Exogenous activation-induced cytidine deaminase 
(AID) enzyme can be expressed introduced into standard cell lines [174, 178], or a 
lentiviral system can be used to transduce hypermutating B-cell lines [177, 179].  Thus at 
any point in the iterative improvement of an antibody, a previously selected libraries can 
be rediversified. 
 
Library construction techniques 
 Antibody repertoires.  Phage display has been widely used as a means of 
searching through vast antibody repertoires.  Sets of light and heavy chains are captured 
from B-cell repertoires by PCR, and are ligated into phagemids designed for display of 
either single-chain antibodies (scFv) or Fabs [180].  The main drawback to such libraries, 
as compared to standard B-cell immortalization techniques, is that original light 
chain/heavy chain pairs are unmatched.  Promiscuous chains that fold well with multiple 
partners tend to predominate [181, 182].  This has led to efforts to create combinatorial 
libraries by chain shuffling [183, 184], and to capture the original pairing by single cell 
PCR [185].   An alternative to native antibody libraries uses randomized CDRs.  This 
randomization can undirected or directed. 
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 Undirected randomization.  The first step in affinity maturation of a protein or 
peptide with known binding characteristics is diversification.  There are two basic 
strategies to randomize libraries in an undirected fashion: low fidelity PCR, and passage 
in a mutagenic host.  Low-fidelity PCR has the advantage of introducing errors only in 
the portion being amplified.  Passage in a mutator strain, such as XL-1 Red [186-188], 
will introduce mutations throughout the plasmid, potentially introducing changes in 
promoter regions that might give a growth advantage to library members, or an avidity 
advantage when expression is increased, thereby increasing valency of display.  As 
mentioned previously, with mammalian display there is also an analogous option of using 
a cell line with AID.  When the target for hypermutation is an antibody, the system for 
somatic hypermutation in stimulated B cells has the advantage of biasing its mutagenesis 
towards sequence found in variable chain regions WRCH (W = A/T, R = A/G, H = 
A/C/T) [189, 190].  Codon-usage biasing toward these sequences could potentially be 
used to promote mutagenic bias in presentation of other proteins and peptides. 
 Directed randomization.  Mutations at specific locations in a POI can be 
directed using PCR primers with mixed bases.  Most frequently this has been done using 
arbitrary equimolar mixes of bases.  These are also referred to as “machine” mixes, as 
mixing is performed at time of synthesis by simultaneous injection of the desired bases.  
Such “hard-randomization” techniques are limited because to have full representation in a 
a library, the number of positions that can be subject to randomization is small (5 or 6 for 
phage display).  This is generally only useful if one has a very good notion of which 
positions are likely to produce productive changes.  An alternative method is “soft-
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randomization”, which permits lower frequency changes over a greater number of 
residues. 
In soft-randomization, diversity is introduced by constructing primers with 
positions biased towards a template or starting-point sequence, mixed with a defined 
percentage of the other three bases in the mix [191-195].  This is also referred to as base 
“doping”.  For example, four mixes may be prepared each containing 85% of one base 
and 5% each of the other three bases (see Chapter 3).  These mixes are used to encode 
soft-randomized positions, providing a bias towards a starting point or template amino 
acid.  Most mutations introduce change of a single position in a codon.  The genetic code 
is organized such that single point mutations are more likely to be conservative.  For 
example, most codons with T in the first position are hydrophobic, all aromatics but 
histidine have T in the second position, etc.  As a consequence, it is possible to distribute 
modest changes along the length of the POI without introducing a large number of 
deleterious mutations.  Such a method is particularly useful in an iterative maturation 
process, where the template for each round of randomization can be based on the best 
output of the previous round (see Chapter 3).  Finally, it is also possible to use both 
techniques simultaneously, as seen in Dennis et al. and Bahudhanapati et al. [192, 194]. 
 
Summary.  The battle between HIV-1 and its host plays out most visibly in the 
constant evolution of Env in competition with the maturation of the antibody repertoire.  
Surface-display technologies allow us to recapitulate some features of this process.  In the 
following sections we will introduce a new phagemid system combining some of the 
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advantages of prokaryotic and mammalian systems.  In Chapter 3 we will demonstrate 
the utility of this system by improving a CD4-mimetic peptide.  In Chapter 4 we describe 
the use of this peptide as a fusion with a CCR5 mimetic to create a double-mimetic 
peptide.  Potential future improvement to these systems will be discussed in a final 
chapter.
34	  
 
 
 
CHAPTER 2 
 
Direct expression and validation of phage-selected peptide variants in mammalian cells 
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2. A.  ABSTRACT 
Phage display is a key technology for the identification and maturation of high 
affinity peptides, antibodies, and other proteins.  However limitations of bacterial 
expression restrict the range and sensitivity of assays that can be used to evaluate phage-
selected variants.  To address this problem, selected genes are typically transferred to 
mammalian expression vectors, a major rate-limiting step in the iterative improvement of 
peptides and proteins.  Here we describe a system which combines phage-display and 
efficient mammalian expression in a single vector, pDQ1.  This system permits 
immediate expression of phage-selected genes as IgG1-Fc fusions in mammalian cells, 
facilitating the rapid, sensitive characterization of a large number of library outputs for 
their biochemical and functional properties. 
 
2. B.  INTRODUCTION 
Phage-display technology is frequently used to identify protein variants that will 
ultimately be produced in mammalian cells or expressed in vivo [193, 196, 197].  
However, bacterially expressed proteins selected as fusions with a phage coat protein do 
not always express or retain their function in mammalian cells, and in standard phage-
display protocols, these defective proteins are retained throughout the selection process 
[196, 198].  Moreover, peptides too small to be expressed by themselves are typically 
first evaluated on the surface of the phage by ELISA, but this approach is quantitatively 
imprecise and retains artifacts from the original selection [191, 199].  This has led to the 
exploration of alternative display methods, such as yeast or mammalian cell-surface 
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display [169, 170, 200].  However, the library sizes possible with these approaches, and 
thus the complexity of the sequence space that can be probed, are orders of magnitude 
lower than that routinely achieved with phage libraries.  To circumvent these difficulties 
while retaining the power of the phage display method, library outputs can be subcloned 
to generate fusion proteins, a time-consuming step that limits the number of outputs that 
can be so evaluated [193, 196, 197, 201, 202].  Expression in bacteria also precludes use 
of certain fusion proteins, notably those with antibody Fc domains.  Fc domains facilitate 
the use of a broad set of commercial tools for purification, immunoprecipitation, flow 
cytometry, and functional studies.  Ideally, one would incorporate such studies early in 
the validation of phage-library outputs [203].  Accordingly, we developed a vector that 
expresses library variants as phage pIII coat-protein fusions in bacterial cells and as 
fusions with the human IgG1 Fc domain in mammalian cells.  This was achieved by 
inserting the machinery of bacterial expression and phage display within the introns of a 
mammalian expression vector. 
 
2. C.  METHODS 
pDQ1 vector construction.  pDQ1, represented in Fig. 2.1A, was constructed by 
inserting an Fc-fusion expression cassette into a pUC-derived plasmid.  A segment 
following the CMV promoter was replaced with sequence encoding the IGH1 signal 
peptide.  The 5’ end of the signal peptide intron was then replaced with sequence 
encoding the Lac operon promoter, a ribosome-binding site and the STII* signal peptide, 
followed by a CD4-mimetic peptide.  The nucleotide and amino acid sequence of the 
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STII* signal peptide is detailed in Fig. 2.1.  Finally, a segment from a pComb3 vector 
[180] encoding the HA tag and the pIII fusion was inserted into the IgG1 hinge-CH1 
intron immediately following the VH1 splice donor. 
Use of the vector.  The current version of the vector has been used for display and 
expression of peptide or scFv, which expresses as scFv-Fc in mammalian cells.  Peptide 
sequence is introduced using inverse PCR.  A minor modification of the vector placed an 
scFv of the CD4-binding site antibody b12 in the vector (not shown) with the restriction 
sites SpeI-BamHI for exchange of scFvs.  A full implementation of the pDQ1 vector is 
described in Chapter 3. 
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Figure 2.1.  The design of pDQ1, a vector for phage-display and mammalian-cell expression of 
protein-Fc fusions. A, A map of pDQ1 is shown, with mammalian (CMV) and bacterial (LacO) 
promoters indicated (purple), as are exon 1 of the heavy chain of IgG1 (IGH1) encoding most of the 
IgG1 signal peptide (blue), STII*, encoding a form of the bacterial signal peptide STII (heat-stable 
enterotoxin II) modified to include a splice acceptor (light blue), the diversified library member (red), 
the phage pIII protein, individual exons comprising the Fc domain of human IgG1 (green), and an SV40 
polyadenylation termination signal (gray). B, Bacterial and mammalian expression cassettes. Phage- 
display uses a cassette including the LacO promoter, and sequence encoding the STII* signal peptide 
and a library component fused to the phage pIII protein. In contrast, mammalian expression utilizes a 
CMV promoter, and encodes a chimera of the IgG1 signal peptide and STII*, the same library 
component, and the Fc domain of IgG1, terminated with an SV40 polyadenylation signal. Note that in 
mammalian cells splicing excises the LacO promoter, most of STII*, and the pIII gene. C, 
Modifications of the bacterial STII signal peptide necessary for expression in mammalian cells. The 
DNA and amino-acid sequences of the C-terminus of the STII signal peptide are shown at top, with the 
signal peptidase cleavage site indicated. This signal peptide functions in bacteria but not in mammalian 
cells. Below that, intronic sequence and the 5’ region of IGH1 exon 2 are shown. This region encodes 
the C-terminus of the IgG1 signal peptide. The 3’ region of the splice acceptor and the site of signal 
peptidase cleavage are indicated. In mammalian cells, IGH exon 2 is spliced to exon 1, encoding the 
complete IGH1 signal peptide. Underneath, sequence encoding the C-terminus of the STII* signal 
peptide is shown. Blue highlighting indicates nucleotides from exon 2 of IGH1 that introduce an 
efficient splice acceptor while retaining signal peptide function in both bacterial and mammalian cells. 
In bacteria, the entire STII* signal peptide is used, whereas in mammalian cells, exon 1 of IGH1 is 
spliced to a short 3’ region of STII*. 
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2.	  D.	  	  RESULTS 
Design of a dual expression vector.  The vector, shown in Fig. 2.1A, exploits the 
fact that splicing occurs only in eukaryotic cells.  Splice donors and acceptors were 
engineered to excise domains specific to phage display and thereby encode a protein-of-
interest fusion with the Fc domain of human IgG1 (Fig. 2.1B). A first splice links regions 
encoding a mammalian signal peptide to one encoding the protein under selection, 
excising sequence encoding a bacterial promoter and signal peptide.  A second splice 
links the gene for the protein under selection to sequence encoding the hinge region of 
IgG1, excising the gene for phage pIII.  Thus in bacteria the vector functions like 
standard phagemid vectors (e.g. pCOMB3) used for phage display [180], whereas when 
transfected into mammalian cells, protein-Fc fusions are expressed.  Our design required 
that the bacterial and mammalian signal sequences share four C-terminal amino acids and 
encode an efficient splice acceptor.  No native bacterial or mammalian sequence met 
these requirements.  However, using splice site and signal peptide prediction programs 
[204, 205], we combined elements from the bacterial STII signal peptide and the 
mammalian IgG1 signal peptide to generate a novel signal peptide (STII*) that allowed 
for efficient expression in both systems (Fig. 2.1C).  The resulting vector, pDQ1, 
expressed Fc-fusion products in mammalian cells as efficiently as the original pCDM8-
derived vector from which the Fc gene was cloned (not shown) [206], and was used to 
produce all the Fc-fusion proteins described here and in Chapter 3. 
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2. E.  DISCUSSION 
Phage display remains a powerful means of improving bioactive peptides and 
proteins that in many cases will ultimately be produced in mammalian cells.  Current 
approaches for validating library outputs limit the number of outputs that can be 
reasonably evaluated or the precision and range of assays that can be applied.  The pDQ1 
vector described here permits early selection for efficient mammalian expression and 
expands the range of available validation techniques.  It thus facilitates immediate, 
sensitive characterization of a large number of library outputs for their biochemical and 
functional properties.  One potentially useful adaptation of this system will be the 
introduction of an Fab library into the vector, facilitating direct production and 
characterization of full-length antibodies in mammalian cells.  With minor modifications, 
this system might also be adapted for mammalian cell surface-display, allowing for a 
preliminary selection in phage followed by subsequent rounds of selection by cell-surface 
display on subsets of manageable size.   This system can also be used without phage 
display, for example when determining a production technology for a particular biologic 
or when the role of a eukaryotic post-translational modification is investigated.  However, 
it is especially useful for phage-display applications.  Because both phage-display and 
mammalian expression from pDQ1 remain as efficient as with single-function vectors, 
we anticipate that mammalian expression will become a standard capability of vectors 
used for phage-based improvement of peptides and proteins. 
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CHAPTER 3 
 
Maturation of a CD4-mimetic peptide 
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3. A.  ABSTRACT 
The pDQ1 is a newly described vector integrating phage display and mammalian 
expression. We demonstrate the utility of this system by improving the ability of a CD4-
mimetic peptide to bind the HIV-1 envelope glycoprotein and neutralize HIV-1 entry.  
We further improved the potency of the resulting peptide, CD4mim6, by limiting its 
ability to induce the CD4-bound conformation of the envelope glycoprotein.  Thus 
CD4mim6 and its variants can be used to investigate the properties of the HIV-1 
envelope glycoprotein and pDQ1 can accelerate the discovery of new peptides and 
proteins through phage display. 
 
3. B.  METHODS 
Library design and assembly.  Primers were designed using four hand-mixes, each 
containing 85% of the template nucleotide and 5% of the remaining three nucleotides. 
Library 1 was constructed using CD4mim2 as a template.  In all cases positions 6, 10, 21-
24 and 26 were held fixed as indicated in Fig. 3.1B.  The remaining positions were soft 
randomized with the appropriate hand mix for the first two codon positions, and 50:50 
G:C mix was used for the wobble position. Library 2 was constructed using CD4mim4 as 
a template. In this iteration, the wobble position was soft-randomized for amino-acids 
encoded by fewer than four codons (K, N, H, Q, D, E, M, I, Y and W) and a 50:50 G:C 
mix was used in the remaining cases (see Fig. 3.2).  The 3’ end of the primer extended 
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outside of the randomization region, and was of sufficient length to have a melting 
temperature ≥ 72°C.  Primers were phosphorylated with T4 PNK (New England 
Biosciences) and used for inverse PCR in 96 well plates with Phusion Flash (Finnzymes).  
The PCR product was pooled, column purified (Qiagen) and ligated with T4 DNA Ligase 
(New England Biolabs).  The ligation product was precipitated using yeast tRNA carrier 
[207] and transformed into MC1061 F’ (Lucigen), titered on LB agar Ampicillin, and 
spread onto multiple 140 mm LB Agar Carbenicillin/Tetracycline/glucose plates. 
Phage production and panning.  Libraries were resuspended from bacterial plates 
using Super Broth + 0.5% glucose and transduced with VCSM13 helper phage 
(Stratagene) as describe in Rader et al. [208]  Briefly, expression was induced overnight 
with SB autoinduction media (yeast extract 2%, tryptone 3%, MOPS 1%, glycerol 0.5%, 
MgCl2 1 mM, glucose 0.05%, lactose 0.05%) containing Carbenicillin (100 mg/L) and 
Kanamycin (50 mg/L).  The supernatant was cleared by centrifugation, passed through a 
0.45 μm filter and precipitated with PEG/NaCl + EDTA.  The pellet was resuspended in 
cold Tris-buffered saline (TBS) and EDTA was added.  gp120-Ig or Fc-only protein A or 
protein G magnetic beads (Invitrogen) were prepared by incubation of gp120-Ig or Fc 
control with beads for 1 hr at 4°C in TBS-TC (0.01% Tween 20, 1% sodium caseinate) 
followed by two washes.  Freshly prepared phage were incubated 10 min with beads and 
washed 10-20 times with TBS-T.  Retained phage were eluted with freshly prepared 1% 
Trypsin in TBS, and eluate was used to transform cultures of NEB F’Iq, and dilutions of 
gp120 and Fc-control cultures were plated to monitor enrichment.  After 1 hour of 
recovery in Super Broth + glucose, cultures were plated as before.  Colonies from the 
titer plates were sequenced to monitor library diversity, and the expansion and panning 
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process was repeated for a total of 3 or 4 pans until the library size was reduced to 
approximately 30 unique clones out of 200 sequences. 
Figure 3.1.  Incorporation of mammalian cell expression and functional assays into the workflow 
of phage display. A, The streamlined phage display workflow used in this study. Plasmids selected in 
panning against target were isolated and used to transfect 293T cells. Library outputs were produced as 
Fc-fusion proteins, which facilitated immunoprecipitation, flow cytometry, and neutralization studies. 
Elements of high performing variants were combined and reassayed. A best composite variant was used 
as a template for a subsequent round of phage-selection and characterization of Fc fusions. B, The 
sequences of the CD4mim variants are shown with description. Blue indicates seven residues held fixed 
through the process, red indicates changes from CD4mim1, a natural amino-acid form of a previously 
described CD4-mimetic peptide. C, An example immunoprecipitation study used to validate library 
outputs. Here, isotopically labeled CD4mim1-6 and CD4-Ig are compared for their abilities to 
precipitate labeled gp120 of the indicated isolate. ADA, YU2, and 89.6 are clade B isolates; SA32, 
ConC, and ZM651 are clade C isolates. Experiment is representative of three with similar results. D, An 
example of a functional study used to characterize library outputs. Here, CD4mim2-Ig, CD4mim4, and 
CD4mim6-Ig are compared using a TZM-bl HIV-1 neutralization assay. Error bars represent a range of 
triplicates. 
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Immunoprecipitation.   Miniprep DNA prepared from sequenced colonies was 
transfected into 12-well plates of 50% confluent 293T cells at 1 μg DNA/well by 
standard calcium phosphate technique. HIV-1 gp120 constructs were transfected into 6 
well plates.  12 hours post-transfection, media was replaced with cysteine/methionine-
negative DMEM containing ExpressLabel (Cole Parmer) and 5% dialyzed calf serum 
Figure 3.2.  The generation of a soft-randomized library using pDQ1. A, Primers used to generate a 
soft-randomized library of CD4mim variants based on a template of CD4mim4. Regions used for 
priming and complementary to the STII* signal peptide (Primer 1) or the second splice donor (Primer 
2) are boxed. Bold red nucleotides indicate hand-mixes at an 85:5:5:5 ratio favoring the original 
template nucleotide. S indicates a 50:50 ratio of G:C, used for wobble positions when an amino acid is 
encoded by four or more distinct codons. Amino acids in bold black are soft-randomized, whereas gray 
amino acids are held fixed. B, Library synthesis. The primers shown in A were phosphorylated and used 
to amplify a linearized pDQ1 vector. The 5.6 kB PCR product was digested with Dpn I to eliminate the 
original vector, and the full-length product was isolated and ligated. Colors correspond to elements of 
text Fig. 2.1. 
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(Invitrogen).  Supernatants were collected 24 hours later, and were cleared by 
centrifugation 2 min at 3,000 rpm, followed by 1 min at 10,000 rpm and complete 
protease inhibitor cocktail (Roche) was added.  Immunoprecipitation assays were 
conducted by incubating normalized quantities of Ig fusions and gp120 supernatants with 
protein A beads for 2 hrs at 4°C with rocking.  Beads were washed 3 times with PBS-
Tween (0.01%) and protein was eluted by heating 10 min at 70°C in NuPage sample 
buffer.  Samples were run on NuPage bis-tris gels, treated with methanol/acetic acid 
fixative and dried on Whatman paper.  Radiolabeled protein was quantified with 
Phosphoimager (Fuji).  
Protein production.  Maxiprep DNA was prepared from 250 mL overnight LB 
cultures of DH5α carrying the pDQ1-CD4mimetic plasmid using PureLink maxiprep kits 
(Invitrogen) according to the manufacturer’s instructions. 293T cells in 140 mm plates 
were transfected with 25 μg/plate at 50% confluency by standard Ca Phosphate 
transfection.  At 12 hrs post-transfection, 10% FCS-DMEM media was replaced with 
serum free 293 Freestyle media (Invitrogen). Media was collected 48 hrs later, debris was 
cleared by centrifugation for 10 min at 1,500g and was filtered in 0.45 μm filter flasks 
(Millipore). Complete protease inhibitor cocktail (Roche) was added to the filtered 
supernatants. 500 μl bed volume of Protein A sepharose beads (GE Healthcare) were 
added and were agitated 4°C overnight. The bead/media mixture was collected by gravity 
flow column (Biorad) and was washed with 30 mL PBS (Lonza) + 0.5M NaCl (0.65M 
NaCl final) followed by 10 mL PBS.  Protein was eluted with 5 mL 2M arginine pH4 into 
1 mL 1M Tris pH 7.5.  Buffer was exchanged for PBS and protein was concentrated to 1 
mg/ml by ultrafiltration (Amicon Ultra) at 3,000g. 
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Surface plasmon resonance studies.  Surface plasmon resonance biosensor data 
were collected on a Biacore 3000 optical biosensor (GE Healthcare).  gp120 of the clade 
C Du151 isolate (Immune Technology Corp.) was coupled to cell 2 or cell 4 of a CM5 
chip using the Amine Coupling Kit (Biacore).  Kinetic data was collected at several 
concentrations of mimetic-Fc fusion proteins, with two repeated concentrations. Surface 
regeneration was by injection of 1M potassium thiocyanate, 1% CHAPSO.  Data were 
analyzed using BIAevaluation software (GE Healthcare) and fit to a 1:1 Langmuir 
binding model. 
HIV-1 neutralization studies.  Pseudotyped virus was produced by coexpression of 
envelope glycoproteins of the indicated HIV isolates, or the VSV-G protein, with 
NL43ΔEnv. 293T cells at 50% confluency in T175 (Falcon) flasks were transfected with 
25 µg of plasmid encoding envelope glycoprotein and 45 μg of NLΔEnv by the standard 
Calcium Phosphate technique. 10% FCS DMEM media was changed at 12 hrs and media 
was collected at 48 hrs.  Viral supernatants were cleared by centrifugation for 10 min at 
1,500g, passed through a 0.45 μm syringe filter (Millipore), and stored at -80°C. 
Neutralization by Fc-fusion constructs was performed according to the protocol described 
in Li et al. [209]  In brief, varying concentrations of CD4-mimetic-Ig or free CD4-
mimetic peptide (NeoBioLab) were incubated with virus at a volume of 100 μl per well 
in 96 well plates for one hour at after which 10,000 cells/well of TZM-bl cells in 100 μl 
of media were added. Plates were incubated 72 hours at 37°C after which 100 μl of media 
was replaced with freshly prepared Brite-Lite reagent (Perkin-Elmer), and luminescence 
data was collected on a Victor3V (Perkin Elmer).  For peptide neutralizations, 10,000 
cells per well were first plated in 96 well plates. 12 hours later, peptide and pseudoviruses 
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were mixed in V-bottom 96-well plates, incubated one hour and then added to the 
adhered cells.  The media was changed after 2 h incubation at 37°C.  All neutralizations 
were performed in triplicate.  
Infection of CCR5-positive, CD4-negative cells.  CF2th-CCR5 cells were incubated 
with pseudoviruses generated with pNL4-3.Luc.R-.E-bearing the indicated HIV-1 
envelope glycoprotein and encoding firefly luciferase in the presence of increasing 
amounts of peptide forms of CD4mim6, CD4mim6W, or soluble CD4.  Infection was 
measured as in neutralization studies. 
Staining of cell expressed HIV-1 envelope glycoprotein.  Cells expressing HIV-1 
envelope glycoprotein trimers were prepared by transient transfection of plasmids 
expressing envelope glycoproteins truncated in the C-terminal cytoplasmic domains to 
facilitate surface expression (gp160-∆CT). T75 flasks of 293T at 50% confluency were 
transfected with 20 μg of plasmid encoding gp160-∆CT and 3 μg of plasmid encoding tat 
by the calcium phosphate technique and incubated overnight.  DMEM + 10% FCS was 
changed at 18 hours post transfection.  Cells were collected 36 hours post transfection by 
treatment with non-enzymatic cell dissociation solution (Sigma), followed by 
centrifugation 5 minutes at 1200 rpm. Cells were resuspended in flow cytometry buffer 
(PBS + 2% Donor Goat Serum + 0.1% sodium azide).  Cells were incubated with Ig-
fusion proteins or the HIV-1 neutralizing antibodies E51 or 2G12 diluted to varying 
concentrations in FACS buffer for 45 min on ice, followed by two FACS buffer washes.  
APC-conjugated anti-human Fc-gamma (Jackson ImmunoResearch) diluted in FACS 
buffer was added and cells were incubated on ice for 30 minutes.  Cells were then washed 
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2 times with flow cytometry buffer and PBS then fixed for flow cytometric analysis with 
1% paraformaldehyde in PBS.  Flow cytometery data were analyzed using FlowJo. 
 
3. C.  RESULTS 
Construction of a ‘soft-randomized’ library.  In a standard phage-display 
workflow, bacteria culture supernatants, periplasmic extracts, or precipitated phage are 
used to initially validate and compare selected phagemid clones.  The alternative 
workflow used here integrates mammalian expression of selected variants, as represented 
in Fig. 3.1A.  As indicated, peptide Fc-fusion proteins were produced directly from pDQ1 
phagemid clones in mammalian cells, and these Fc-fusion proteins were assayed with a 
range of techniques. 
Here, for example, immunoprecipitations of HIV-1 gp120, the target protein, were 
performed using metabolically labeled supernatants of transfected 293T cells.  In parallel, 
promising peptide-Fc variants were compared using flow cytometry, HIV-1 
neutralization studies, and surface plasmon resonance.  Elements from optimal variants 
were then combined, and the composite peptide that best bound gp120 and neutralized 
HIV-1 then served as the template for a new phagemid library and a subsequent round of 
selection. 
We began with a previously described CD4-mimetic peptide that included three 
unnatural amino acids [138, 146, 210].  These amino acids were reverted to their closest 
natural form, introducing a cysteine at position 1, a phenylalanine at position 23, and a 
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valine at position 27 to generate CD4mim1 (Fig. 3.1B).  In order to facilitate N-terminal 
fusions of this peptide with CCR5-mimetic peptides [78, 112], and to expand the 
conformational space available to peptide variants, the first of three disulfide bonds was 
eliminated (CD4mim2).  Note that CD4mim2 bound gp120 with lower affinity than 
CD4mim1, presumably due to the loss of this disulfide bond.  CD4mim2 was used as a 
template to generate a first library of CD4mim variants.  CD4mim4, the final composite 
product of our first selection cycle, was used as a template for a second library and 
another round of selection.  Both libraries were ‘soft-randomized’ from their respective 
templates. 
Soft randomization is a diversification technique that permits the introduction of a 
small number of amino-acid changes (e.g. 5) distributed throughout a larger peptide (e.g. 
the 28 amino-acids of CD4mim2 and CD4mim4).  This approach allows modest changes 
along the length of the peptide without introducing a large number of mutations likely to 
be deleterious [191, 193, 195].  Fig. 3.2 details our procedure for library construction 
using pDQ1 and soft-randomized oligonucleotides.  Seven amino acids were held fixed: 
the four remaining cysteines and a “GSF” region identical to the key gp120-binding 
residues of CD4 (residues 41-43 [210]), whereas the remaining twenty-one residues were 
encoded by doped oligonucleotides favoring template amino acids at an 85:5:5:5 ratio.  
This library was panned against HIV-1 gp120 (those of the clade B isolate ADA and the 
clade C isolate ZM651, see Methods).  Selected CD4mim variants were expressed as 
peptides-Fc fusions in 293T cells and used to compare output variants for functional 
activity in immunoprecipitation and HIV-1 neutralization assays (Figs. 3.1C and 3.1D for 
example).  Elements of selected variants were combined and resulting proteins were 
53	  
again compared. In this way, an optimal peptide was selected as a template for a second 
soft-randomized library.  The procedure was repeated, and an improved peptide, 
CD4mim6, was selected.  Fig. 3.3 details the process by which CD4mim6 was developed 
as a composite of several library outputs. 
 
 Enhanced neutralization of HIV-1 by CD4mim6.  Because CD4mim1, with 
three disulfide bonds, outperformed in immunoprecipitation and neutralization assays our 
starting point, CD4mim2, with two disulfide bonds (Fig. 3.1D and not shown), we 
compared the properties of our final product, CD4mim6, with CD4mim1, using Fc 
fusions of both variants.  Both peptides bound measurably to 293T-cell surface expressed 
Figure 3.3.  The development of CD4mim6. The sequence of CD4mim4, the template for a second 
soft-randomized library, is shown along with a representative panel of outputs from this library panned 
against a clade B (ADA) and clade C (ZM651) isolate. Outputs by immunoprecipitation (for example 
Fig. 2C), flow cytometry (e.g., Fig. 3A) and neutralization studies (e.g. Figs. 2D and 3C) identified best 
performers whose elements were recombined. The resulting composite variants were reassayed, and an 
optimal variant, in this case, CD4mim6 was identified. As shown CD4mim6 combines elements of 
CD4mim5, the best output from this screen, and two additional good outputs. 
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HIV-1 envelope glycoprotein trimers (Fig. 3.4A). However, at all concentrations, and for 
all clade B and C envelopes assayed, CD4mim6-Ig bound more efficiently than 
CD4mim1-Ig, and similarly to CD4-Ig.  Surface plasmon resonance studies with 
immobilized gp120 (Du151, clade C) made clear that the basis for the efficient binding 
was due to a slower off-rate, five times slower for CD4mim6-Ig. In fact, CD4mim6-Ig 
had a modestly slower on-rate, presumably due to its greater flexibility (Fig. 3.4B).  More 
total CD4mim6-Ig bound to immobilized gp120, perhaps indicating that the more flexible 
CD4mim6-Ig accessed more gp120 conformations than the fixed CD4mim1-Ig. 
CD4mim6-Ig also efficiently neutralized clade B and clade C HIV-1 isolates at 
concentrations (1-2 µg/ml; 20-40 nM) where no neutralization was observed for 
CD4mim1-Ig (Fig. 3.4C).  When CD4mim1 and CD4mim6 were synthesized as free 
peptides without an Fc domain, CD4mim6 efficiently neutralized HIV-1, again at 
concentrations where no neutralization was observed from CD4mim1 (Fig. 3.4D). 
Figures 3.5A and B shows a model of CD4mim6 bound to HIV-1 gp120, with changes 
from CD4mim1 highlighted. 
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Figure 3.4.  Comparisons of CD4mim1-Ig and CD4mim6-Ig. A, Binding of CD4mim-Ig variants and 
CD4-Ig to 293T cells transfected to express the trimeric envelope glycoproteins of the indicated clade B 
(HXB2, ADA, 89.6) and clade C (SA32) isolates. Binding was determined by flow cytometry using a 
goat anti-human secondary antibody. Background binding, determined using Fc domain alone was less 
than 15 mean fluorescence intensity in each case. Experiment is representative of two with similar 
results. B, Surface-plasmon resonance studies of CD4mim1-Ig and CD4mim6-Ig using immobilized 
gp120 of the clade C isolate Du151. Results are shown with thick lines. Thin black lines represent 
global fitting of the data to a 1:1 Langmuir binding model. C, CD4mim6-Ig neutralizes clade B (HXB2) 
and clade C (SG3, SA32) HIV-1 isolates with IC50s of 1-2 μg/ml (20-40 nM), whereas no 
neutralization was observed for CD4mim1-Ig at 8 μg/ml (160 nM), and HIV-1 pseudotyped with VSV-
G protein was unaffected by any Fc fusion. Experiment is representative of three with similar results. D, 
Synthetic monomers of CD4mim1 and CD4mim6 were compared in the same assay. CD4mim6 
neutralized the indicated isolates with IC50s in the 0.5-2 μg/ml range, whereas IC50s for CD4mim1 
were greater than 4-8 μg/ml. Experiment is representative of two with similar results. Error bars in all 
cases represent a range of duplicates (A) or triplicates (C and D). 
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CD4mim6 as a tool for understanding neutralization of HIV-1.  To determine the 
similarity between CD4mim6 and sCD4, we incubated CD4mim6 with cells expressing 
the HIV-1 envelope glycoprotein ADA, and measured its ability to promote association 
with the CD4-inducible antibody E51 (Fig. 3.6A).  CD4mim6 increased association of 
E51 with the envelope glycoprotein, but had no effect on an HIV-1 neutralizing antibody, 
2G12, that is unaffected by CD4 association.  In parallel, we assayed a CD4mim6 variant, 
Figure 3.5.  A model of CD4mim variants with alterations indicated. A, CD4mim1 is a natural 
amino- acid form of CD4M33, a CD4-mimetic peptide built from a scorpion toxin scaffold, with three 
disulfide bonds. Residues held constant during the library construction are indicated in blue. For 
CD4mim2, cysteines 1 and 19 were altered to glycine and leucine, respectively, shown in red. 
CD4mim4, the product of the first cycle of phage selection and the template the second phage library 
has eight total differences from CD4mim1, again indicated in red (see Fig. 2B for changes). CD4mim6, 
the final product of the second cycle, has twelve such differences. B, CD4mim6 modeled into the CD4-
binding site of HIV-1 gp120. All models are based on the Protein Data Bank structure 1YYM by Huang 
et al. (20) and generated with the PyMOL mutagenesis tool. 
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CD4mim6W, in which phenylalanine 23 was replaced with a tryptophan.  Phenylalanine 
23 binds a critical pocket of HIV-1 gp120 also occupied by CD4 phenylalanine 43.  
Occupation of this same gp120 pocket with a tryptophan has been shown to increase the 
potency of the neutralizing antibody NIH-45-46 [211].  Strikingly, CD4mim6W did not 
enhance binding of E51 to HIV-1 envelope glycoprotein.  We speculated that it would 
therefore be unable to promote infection when cellular CD4 was limiting, in contrast to 
both sCD4 and CD4mim6.  Indeed with CD4-negative, CCR5-high cells, infection 
increased with increasing concentration of sCD4 or CD4mim6 (Fig. 3.6B).  However, 
little or no infection was observed at any concentration with CD4mim6W.  Consistent 
with these observations, CD4mim6W more potently neutralized HIV-1 than CD4mim6 
(Fig. 3.6C).  Thus the potency of CD4mim6 and perhaps CD4-binding site antibodies 
may be attenuated by their tendency to promote infection when cellular CD4 is limiting. 
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Figure 3.6.  CD4mim6, but not CD4mim6W, induces the CD4-bound conformation of the HIV-1 
envelope glycoprotein. A, 293T cells transfected to express the envelope glycoprotein of the clade B 
isolate ADA were incubated with the indicated concentrations of CD4mim6 or CD4mim6W, a variant 
in which phenylalanine 23 was replaced with a tryptophan. Cells were then incubated with an anti-
gp120 antibody, either the CD4-inducible antibody E51(250 ng/mL for 89.6; 50 ng/mL for ADA) or the 
anti- glycan antibody 2G12 (250 ng/mL). Binding was determined by flow cytometry using a goat anti-
human secondary antibody. Background binding, determined using Fc domain alone was less than 15 
mean fluorescence intensity in each case. Experiment is representative of two with similar results. B, 
CCR5- high, CD4-negative Cf2Th cells were incubated with an ADA pseudovirus encoding firefly 
luciferase in the presence of the indicated concentrations of CD4mim6, CD4mim6W, or soluble CD4 
(sCD4). Infection, measured as luciferase activity (RLU) was determined as in Fig. 3.4C. C, 
Neutralization studies of CD4mim6-Ig and CD4mim6W-Ig as described in Fig. 3.4C. 
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3. D.  DISCUSSION 
The CD4-mimetic peptide generated in these studies is unlikely by itself to serve as a 
therapeutic.  However, a small peptide that mimics CD4 can be especially useful as a tool 
for understanding neutralization of HIV-1.  Its size ensures that it will not sterically 
interfere with binding of antibodies to the HIV-1 envelope glycoprotein.  It therefore can 
be used with various antibodies to compare the CD4-bound and unliganded states of the 
envelope glycoprotein.  Further study of CD4mim6W may also deepen our understanding 
of the different conformational states available to gp120 and the envelope glycoprotein 
trimer.  
Although the therapeutic potential of CD4mim6 alone is limited, it may be more 
potent as a fusion with other inhibitors.  CD4mim1 has been fused at its carboxy-
terminus with tyrosine-sulfated CCR5-mimetic peptides to make a ‘double-mimetic’ 
peptide with considerably higher potency than either peptide alone [78].  CD4mim6 
possess two advantages over CD4mim1 in this context.  First, it binds gp120 with higher 
affinity and neutralizes HIV-1 more efficiently than CD4mim1.  Second, some steric 
interference between the amino-terminus of CD4mim1 and gp120 has been observed 
[138], precluding N-terminal fusions with this mimetic.  By eliminating the first disulfide 
bond of CD4mim1, the amino-terminus of CD4mim6 can now be readily fused to a 
CCR5-mimetic peptide, positioning the latter mimetic much closer to its binding pocket.  
These kinds of constructs induce the CD4-bound conformation of the trimer, and 
therefore can potentially synergize with gp41-derived peptides such as T20/enfuvirtide.  
Further improvement of both double and single mimetic peptides, and of neutralizing 
antibodies that target HIV-1 and other pathogens, can be significantly accelerated using 
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the pDQ1 system described here.
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CHAPTER 4 
 
A double-mimetic peptide efficiently neutralizes HIV-1 by bridging the CD4- and 
coreceptor-binding sites of gp120 
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4. A.  ABSTRACT 
We show that fusions of CCR5- and CD4-mimetic peptides, expressed as 
immunoadhesins, neutralize HIV-1 more efficiently than CD4-Ig or mixtures of 
immunoadhesin forms of each peptide.  Specifically, double-mimetic peptides with 
linkers of 11 amino acids in which the CCR5-mimetic component precedes the CD4-
mimetic component were more efficient than constructs with shorter linkers or a reverse 
orientation.  These fusion proteins bridge the CD4- and CCR5-binding sites of HIV-1 
gp120 to achieve their greater potency.  
 
4. B.  INTRODUCTION 
Human immunodeficiency virus type 1 (HIV-1) entry requires cellular expression 
of CD4 and a coreceptor, principally CCR5 or CXCR4 [10, 11, 13, 212].  Small CD4-
mimetic peptides, based on a scorpion-toxin scaffold, bind the HIV-1 envelope 
glycoprotein (Env) and inhibit HIV-1 entry [145, 146, 213].  These peptides induce the 
CD4-bound conformation of gp120 and, like soluble CD4, can promote infection when 
cellular CD4 is limiting [78, 213, 214].  Sulfopeptide mimetics of the tyrosine-sulfated 
CCR5 amino-terminus also bind gp120 and inhibit HIV-1 entry [112, 148].  These 
peptides bind inefficiently in the absence of CD4, but more efficiently when gp120 is 
bound by CD4 or a CD4-mimetic peptide [78, 112, 148].  We reasoned that fusions of a 
CD4 and CCR5-mimetic peptides (represented in Fig. 4.1) would bind gp120 
cooperatively, and that the CCR5-mimetic peptide would limit the ability of the CD4-
mimetic peptide to promote infection. 
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4. C.  METHODS 
Plasmids and cells.  Double-mimetic peptides and all mutations were created using 
inverse PCR on a pUC19-derived plasmid carrying the expression cassette from the 
previously described pCDM8-derived plasmid expressing the signal sequence of CD5 
and the Fc domain of human IgG1 [215] using Phusion Flash Mix (Thermo/Finnzymes) 
Figure 4.1.  Receptor-mimetic constructs. A, Sequences of the single- and double-mimetic peptides 
used in this work. Blue indicates CCR5mim3 and red indicates CD4mim6. Linker regions are not 
highlighted. B, Diagram of mimetic-Fc fusions constructs. CCR5mim3 is shown as a blue circle, 
CD4mim6, as a red circle, and the Fc domains are indicated in grey. C, Ribbon diagram of HIV-1 
gp120 (grey), bound to a CD4-mimetic peptide (red) and sulfotyrosines (blue). Sulfotyrosines derive 
from the heavy chain of the CD4-inducible antibody 412d. Figure was generated by aligning the gp120 
molecules of the gp120-CD4-412d complex (2QAD) with the gp120-F23 complex (1YYM) [62,146].  
Dashed line indicates the 28 angstrom distance from the amino-terminal α-carbon of the CD4 mimetic 
to the α-carbon 412d sulfotyrosine 100. 
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with added sequence and or mutations encoded by phosphorylated primers.  Products 
were ligated using T4 DNA Ligase (NEB) and transformed into DH5α.  Plasmids 
encoding monomeric Fc forms were generated by altering the human IgG1 Fc domain 
codons to encode the following changes: C219A, C226N, C229G, N297D, L368R, 
F405H, and Y407E (numbering according to the Kabat database).  Plasmids expressing 
HIV-1 gp120s and gp160s have been described previously [78]. Human embryonic 
kidney 293T and TZM-bl cell lines were obtained from the American Type Culture 
Collection. 
Protein production.  Maxiprep DNA was prepared from 250 mL overnight LB 
cultures of DH5α carrying the Amp resistant plasmids using PureLink maxiprep kits 
(Invitrogen) according to the manufacturer’s instructions. 293T cells in 140 mm plates 
were transiently transfected with 25 μg/plate at 50% confluency by standard Ca 
Phosphate transfection.  At 12 hrs post-transfection, 10% FCS-DMEM media was 
replaced with serum free 293 Freestyle expression media (Invitrogen).  Culture 
supernatants were harvested 48 hrs later, debris was cleared by centrifugation for 10 min 
at 1,500g and was filtered in 0.45 μm filter flasks (Millipore). Complete protease 
inhibitor cocktail (Roche) was added to the filtered supernatants. 500 μl bed volume of 
Protein A sepharose beads (GE Healthcare) were added and were agitated overnight at 
4°C. The bead/supernatant mixture was collected by gravity flow column (Biorad) and 
was washed with 30 mL PBS (Lonza) + 0.5 M NaCl (0.65 M NaCl final) followed by 10 
mL PBS.  Protein was eluted with 5 mL 2 M arginine pH4 into 1 mL 1 M Tris pH 7.5.  
Buffer was exchanged for PBS and protein was concentrated to 1 mg/ml by 
Ultrafiltration (Amicon Ultra) at 3,000g. 
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HIV-1 neutralization studies.  Pseudotyped virus was produced by coexpression of 
envelope glycoproteins of the indicated HIV isolates with NL43ΔEnv. 293T cells at 50% 
confluency in T175 (Falcon) flasks were transfected with 25 µg of plasmid encoding 
envelope glycoprotein and 45 μg of NLΔEnv by the standard Calcium Phosphate 
technique. 10% FCS DMEM media was changed at 12 h and media was collected at 48 
hrs post-transfection.  Viral supernatants were cleared by centrifugation for 10 min at 
1,500g, passed through a 0.45 μm syringe filter (Millipore), and stored at -80°C. 
Neutralization by Fc-fusion constructs was performed according to the protocol described 
in Li et al. [209].  In brief, varying concentrations of purified Fc fusion proteins were 
incubated with virus at a total volume of 100 μl per well in 96 well plates for one hour 
after which 10,000 cells/well of TZM-bl cells in 100 μl of media were added. Plates were 
incubated 72 h at 37°C after which 100 μl of media was replaced with freshly prepared 
Brite-Lite reagent (Perkin-Elmer), and luminescence data was collected on a Victor3V 
(Perkin Elmer).  All neutralizations were performed in triplicate.  
Infection of CCR5-positive, CD4-negative cells.  CF2th-CCR5 cells were incubated 
with pseudoviruses generated with pNL4-3.Luc.R-.E-bearing the indicated HIV-1 
envelope glycoprotein and encoding firefly luciferase in the presence of increasing 
amounts of CD4-mimetic (CD4mim6-Fc) double-mimetic (11-Fc) or CD4-Fc.  Infection 
was measured as in neutralization studies. 
Immunoprecipitation.  HIV-1 gp120 constructs were transfected into 6-well plates 
of 50% confluent 293T cells at 1 μg DNA/well by standard calcium phosphate technique. 
12 h post-transfection, media was replaced with cysteine/methionine-negative DMEM 
containing ExpressLabel (Cole Parmer) and 5% dialyzed calf serum (Invitrogen).  
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Supernatants were collected 24 h later, and were cleared by centrifugation for 2 min at 
3,000 rpm, followed by 1 min at 10,000 rpm and complete protease inhibitor cocktail 
(Roche) was added.  Immunoprecipitations were conducted by binding 1 μg of Fc or 
monomeric Fc constructs to protein A beads for 2 hrs at 4°C with rocking.  Beads were 
then washed twice with PBS-Tween (0.01%) and 35S-radiolabeled gp120 was added and 
incubated an additional 2 hrs at 4°C with rocking.  Beads were washed 3 times with PBS-
T and protein was eluted by heating 10 min at 70°C in NuPage sample buffer.  Samples 
were run on NuPage bis-tris gels, treated with methanol/acetic acid fixative and dried on 
Whatman paper.  Radiolabeled protein was quantified with Phosphoimager (Fuji). 
Staining of cell expressed HIV-1 envelope glycoprotein.  Cells expressing HIV-1 
envelope glycoprotein trimers were prepared by transient transfection of plasmids 
expressing envelope glycoproteins truncated in the C-terminal cytoplasmic domains to 
facilitate surface expression (gp160-∆CT). T75 flasks of 293T cells at 50% confluency 
were transfected with 20 μg of plasmid encoding gp160-∆CT and 3 μg of plasmid 
encoding Tat by the calcium phosphate technique and incubated overnight.  DMEM + 
10% FCS was changed at 18 h post transfection.  Cells were collected 36 h post 
transfection by treatment with non-enzymatic cell dissociation solution (Sigma), followed 
by centrifugation for 5 m at 1200 rpm. Cells were resuspended in flow cytometry buffer 
(PBS + 2% Donor Goat Serum + 0.1% sodium azide).  Cells were incubated with Fc-
fusion proteins diluted to varying concentrations in FACS buffer for 45 min on ice, 
followed by two FACS buffer washes.  APC-conjugated anti-human Fc-gamma (Jackson 
ImmunoResearch) diluted in FACS buffer was added and cells were incubated on ice for 
30 m.  Cells were then washed 2 times with flow cytometry buffer then fixed for flow 
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cytometric analysis with 1% paraformaldehyde in PBS.  Flow cytometery data were 
analyzed using FlowJo. 
 
4. D.  RESULTS 
Inspection of the structure of gp120 bound to one CD4-mimetic peptide, F23, 
indicated that its amino-terminal residue was held by a disulfide bond in an orientation 
that sterically precluded fusion at its amino-terminus [146, 213].  Also, its carboxy-
terminus was oriented away from the gp120 sulfotyrosine binding pockets, and likely 
required a prohibitively long linker to allow for both mimetic peptides to bind 
simultaneously (Fig. 4.1C).  We accordingly modified a natural amino-acid form of this 
CD4-mimetic peptide to remove its first disulfide bond and permit the addition of amino-
terminal linkers [213].  The affinity of this peptide was subsequently improved by phage-
display [213].  
Using this improved CD4-mimetic peptide, CD4mim6 [213], and CCR5mim3, a 
shortened form of a previously described CCR5 mimetic peptide [148], we produced a 
series of CCR5mim3/CD4mim6 fusion proteins separated by linkers of 1, 6, 11, and 16 
amino acids (1-Fc, 6-Fc, 11-Fc, 16-Fc; Fig. 4.1A) and a reverse CD4mim6/CCR5mim3 
fusion protein with a linker of 11 amino acids (Rev-Fc; Fig. 4.1A-B).  The fusion protein 
with the shortest linker, 1-Fc, was consistently the least efficient at neutralizing HIV-1, 
and was in most cases less efficient than CD4-Ig (Fig. 4.2A).  Fusion proteins with linker 
lengths of 11 and 16 neutralized all HIV-1 isolates with comparable efficiency, and with 
markedly greater efficiency than CD4-Ig.  With some isolates (HXB2, SG3) 6-Fc, with a 
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six amino-acid linker, neutralized as efficiently as 11-Fc and 16-Fc.  With others (89.6, 
BaL), 6-Fc was clearly less efficient than 11-Fc.  These data suggest that, with linkers of 
11 or greater, both mimetic peptides are engaged, likely to the same gp120 monomer.  
Consistent with this, mixtures of both mimetic peptides alone, each at the same total 
concentration as 16-Fc, neutralized HIV-1 much less efficiently than 16-Fc (Fig. 4.2B).  
Similarly, Rev-Fc, a construct in which the order of mimetic peptides was reversed, also 
neutralized less efficiently than 16-Fc (Fig. 4.2B).  Thus 11-Fc and 16-Fc potently 
neutralize HIV-1, likely because they simultaneously bind the CD4- and coreceptor-
binding sites of gp120. 
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Figure 4.2.  Neutralization assays of single- and double-mimetic peptides. A, HIV-1 pseudotyped 
with the envelope glycoproteins of the indicated HIV-1 isolates were incubated with TZM-bl cells and 
with CD4-Fc or double-mimetic Fc fusions varying in linker length. Infection was determined by 
luciferase activity 48 hours later. B, Assay similar to that in A except that CD4mim6-Fc, CCR5mim3-
Fc, a mixture of these constructs, Rev-Fc, 16-Fc, and CD4-Fc were assayed. All neutralization studies 
were performed in triplicate, with bars representing standard error. Experiments are representative of 
two with similar results.  
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The neutralization activity of soluble CD4 and CD4-mimetic peptides can be 
attenuated by their parallel tendency to promote infection, possibly by promoting 
interaction of the HIV-1 envelope glycoprotein with the coreceptor [79, 216].  We 
therefore sought to determine if CCR5mim3 prevented induction of infection by 
CD4mim6, explaining in part the potency of 11-Fc.  Both CD4-Fc and CD4mim-Fc 
enhanced HIV-1 infection in cells expressing CCR5 but not CD4, whereas 11-Fc did not 
(Fig. 4.3).  Thus the CCR5mim3 domain of 11-Fc blocks the ability of CD4mim6 to 
promote infection. 
 
Double mimetic peptides with sub-optimal linkers or orientations still neutralize 
better than mixtures of CCR5mim3-Fc and CD4mim6-Fc (Fig 4.2B), perhaps because 
gp120 binds CCR5mim3 from one arm of the Fc dimer and CD4mim6 from the opposite 
arm.  To explore this possibility we generated monomeric Fc forms of 1-Fc and 16-Fc 
Figure 4.3.  Infection of CCR5-positive, CD4-negative cells.  CCR5-high, CD4-negative Cf2Th cells 
were incubated with the indicated pseudoviruses encoding firefly luciferase in the presence of the 
indicated concentrations of CD4-Fc, CD4mim6-Fc, and 11-Fc. Infection, measured as luciferase 
activity as in Fig. 2. Numbers represent relative luciferase normalized to largest value. Experiment was 
performed in triplicate, with bars representing standard error. 
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(mono 1-Fc, mono 16-Fc (see Fig. 4.1B) [78].  These variants were compared with 
dimerized forms of the same constructs by flow cytometry with cells expressing HIV-1 
envelope glycoprotein trimers (Fig. 4.4A), in neutralization studies (Fig. 4.4B), and by 
immunoprecipitation of radiolabeled gp120 (Fig. 4.4C).  In each assay, the dimer form of 
16-Fc modestly outperformed the monomer form of 16-Fc and dimer form of 1-Fc.  All 
three of these constructs bound envelope glycoprotein trimers, precipitated gp120 and 
neutralized HIV-1 markedly more efficiently than monomeric 1-Fc.  Fig. 4.4D diagrams 
our interpretations of this data, namely that monomeric and dimeric 16-Fc, and dimeric 1-
-Fc can bind both receptor sites on gp120, but monomeric 1-Fc can bind only one.  Note 
that the monomeric Fc appears to expose a protease site in the CH3 Fc domain, but that 
this cleavage does not interfere with its association with Protein A or the binding and 
neutralization activities of monomeric fusion constructs. 
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Figure 4.4.  Comparison of monomer and dimer forms of double-mimetic peptides.  Monomeric 
and dimeric Fc fusions of the indicated double mimetic peptides were assayed by: A, cell-surface 
binding to 293T cells expressing the envelope glycoprotein of the ADA isolate, as measured by flow 
cytometry; B, neutralization studies, as described for Fig. 2; C, precipitation of [35S]-cysteine-labeled 
gp120 by Fc-fusions bound to Protein A-sepharose beads. D, A model explaining the precipitation 
results in C. Figures A-C were performed in triplicate, with bars indicating standard error, and are 
representative of at least two experiments with similar results. 
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4. E.  DISCUSSION 
Collectively our data describe a novel class of peptide inhibitors of HIV-1 entry, 
namely those that can simultaneously bind both the receptor- and coreceptor-binding sites 
of gp120.  These peptides are more potent than any single-mimetic peptide that targets 
gp120, and indeed more potent than CD4-Ig.  Interestingly, each component 
complements a weakness of the other.  CCR5-mimetic peptides like CCR5mim3 bind 
gp120 inefficiently, but their affinity increases in the presence of CD4-mimetic peptides 
or soluble CD4.  CD4-mimetic peptides like CD4mim6 bind more efficiently, but they 
tend to promote infection when cell-expressed CD4 is limiting.  CCR5mim6 prevents 
this, presumably by blocking access to cell-expressed CCR5.  With appropriate linkers, 
double-mimetic peptides also benefit from the increased avidity by binding two discrete 
and conserved sites of gp120. 
Despite these advantages, these peptides have several limitations as therapeutics.  
First, the CD4-mimetic component is considerably less broad than soluble CD4 or the 
best CD4-binding site antibodies [213].  Of course, further broadening of this component 
through phage-based improvement or perhaps an alternative design is possible.  Second, 
the presence of multiple sulfotyrosines complicates chemical synthesis [217].  However 
bacterial expression systems have been developed which can incorporate sulfotyrosines 
during translation [218, 219].  Finally, like any peptide, those of this class cannot be 
administered orally, and given the wide array of oral therapeutics now available, these 
peptides at best might be useful as part of a microbicide.  However, as this study 
illustrates, these peptides are useful as probes of the structure and function of the HIV-1 
envelope glycoprotein. 
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CHAPTER 5: DISCUSSION 
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The current work has highlighted a number of features of HIV-1 Env and its 
inhibitors, while describing four key technologies.  In Chapter 2 we described a novel 
phage display vector that expresses selected products in mammalian cell culture, greatly 
streamlining the iterative improvement of immunoadhesins and peptides.  In Chapter 3 
we demonstrated the utility of this vector by using it to improve a CD4-mimetic peptide, 
and described the use of this peptide in probing Env structure and function.  In Chapter 4 
we combined this improved peptide together with a coreceptor-mimetic peptide to 
generate a double-mimetic peptide more potent than the sum of its parts.   Finally, in the 
process of improving our mimetic peptides, we used controlled diversification techniques 
with applications beyond phage display.  
In the following sections, we discuss how each of these technologies might be 
extended, and discuss some aspects of Env function that this work has highlighted.  First 
two useful extensions of the pDQ1 vector are described: immediate mammalian 
expression of whole antibodies derived from phage selection of Fabs, and a single screen 
combining the strengths of phage and mammalian display technologies.  An approach to 
further enhancing the breadth and potency of the CD4-mimetic is then described, together 
with a discussion of the tendency of this mimetic to augment infection under certain 
conditions.  This augmentation complicates efforts to substantially increase the potency 
of this class of inhibitors.  The double-mimetic peptide, which solves this problem, is 
then discussed, as well as some of the issues associated with further improving its 
potency.  Finally, we describe a novel use of the directed diversification techniques with 
the pDQ1 to improve the CD4-mimetic.  Specifically we discuss how it might be applied 
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to obtaining a comprehensive picture of pathways of viral escape from antibodies 
inhibitors such as those described here. 
  
The dual-display vector technology 
 Development of the dual-display vector.  The selection of protein variants from 
phage-display libraries presents particular challenges when expression of the selected 
variants necessarily involves expression in mammalian cell culture.  Thus, it is often 
necessary to introduce a subcloning step into the process.  Also it is particularly 
convenient at this point to express these variants as fusions to IgG Fc fragments, thereby 
enabling further characterization of these variants using a range of tools.  Due to 
differential growth and expression artifacts, variants enriched by panning are not 
necessarily those that best bind when expressed from mammalian cells.  Therefore, it is 
desirable to evaluate as many output variants as possible in mammalian cell culture, as 
early as possible in the process.  The dual-display vector that we have described (pDQ1) 
allows for direct expression of output variants when transfected in mammalian cell 
culture, greatly streamlining this process.  This, however, is just the beginning of the 
potential uses of this type of vector.  We anticipate two adaptations of pDQ1: for the 
display of Fabs (which we can then express as full-length IgG in tissue culture), and the 
useful integration of phage and mammalian surface display systems. 
Dual-display of Fab and antibody libraries.  The pDQ1 vector can be readily 
adapted for the display of Fabs. A full-length IgG consists of two Fabs and an Fc 
fragment.  Using this system, outputs from the Fab library could be immediately 
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expressed as full-length antibodies in mammalian cell culture without subcloning.  There 
are two alternative strategies to accomplishing this end.  A fairly simple implementation 
would be a two-plasmid system, one each for heavy and light chain.  Only one chain at a 
time is diversified, and only that plasmid would bear a phage origin of replication.  After 
an initial round of transformation and helper phage rescue for the diversified chain alone, 
progeny phage would be used to transduce E. coli in which the undiversified chain is 
being maintained with different antibiotic resistance. For example, plasmid bearing the 
phage ori and a diversified heavy chain would have ampicillin resistance, and the second, 
bearing a fixed light chain would have chloramphenicol resistance.  Both would have a 
mammalian expression cassette with the bacterial promoter and signal sequence 
embedded in the mammalian signal sequence intron, as is pDQ1 (see Fig. 2.1C).  
However, only the heavy-chain construct would have the pIII fusion, which would be 
embedded in the IVS1 intron directly before the Fc hinge.  Rescue of this library would 
provide phage that displays a complete Fab, which then would be used for the initial 
round of panning.  If it were desirable to diversify both heavy and light chains, one could 
do so by alternating rounds of library construction and selection. The same plasmids, 
selected from phage panning, would be cotransfected for production of full length IgG in 
mammalian tissue culture. 
A second potential implementation would insert both heavy and light chains into 
the same plasmid.  This approach would allow for simultaneous diversification of both 
chains, but it requires a larger, more complicated construct, and the mammalian 
expression product would differ slightly from a native IgG.  The light chain would come 
first, followed by a 2A “protease” ribosomal skip sequence, which would include a strong 
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intron, within which a stop codon for the light-chain Fab would be embedded.  This 
sequence would be followed by a second bacterial promoter, and a signal sequence for 
the heavy chain.  In mammalian cell culture, the heavy chain would differ from native 
IgG by a proline at its N-terminus.  The C-terminus of the light chain would bear the 
remainder of the 2A sequence, unless a furin cleavage site were placed before it, in which 
case the majority would be cleaved off, and then trimmed down to native sequence by 
carboxypeptidase B.  The size of this plasmid (6.9 kb) would be on the large side for 
phage display, and careful handling would be required to avoid overgrowth by truncated 
phagemids, but this size is well within the packaging capabilities of filamentous phage. 
Integrating Phage and Mammalian Display.  Mammalian display libraries are 
constrained by the size of the initial library at the time of construction and by the limited 
throughput of panning by cell sorting.  The size of the initial library is tied to the number 
of cells at maximum expansion.  Many variants will be cotransfected, with the variants 
per cell declining over time due to asymmetric segregation as the cells divide.  The 
limited throughput is due to the serial rather than parallel nature of cell sorting, where the 
maximum throughput is determined by events per second of the cell sorting.  Limited 
throughput can be circumvented using magnetic cell sorting in an initial round of 
selection.  The dual display system of the pDQ1 vector could be easily adapted for use as 
a mammalian display system, allowing the initial magnetic bead selection of a very 
complex library to be performed in a phage system.  The much simplified, partially 
selected library would then be transferred to mammalian display selection system for 
later rounds of selection.   
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The simplest adaptation would add a transmembrane domain, such as the 
PDGFR-TM used in the pDisplay system, to the C-terminus of the Fc domain.  For 
panning purposes, only a small fraction of the secreted Fc needs to be expressed at the 
surface.  It is possible to retain use of the soluble variant-Fc fusions by implementing an 
alternative splice system such as seen in Horlick et al. [178].  In this system, an 
inefficient splice acceptor removes a stop codon containing sequence, allowing 
readthrough to a transmembrane domain on a minority of mRNA scripts.  Another 
alternative uses inducible readthrough translation: a leaky stop codon would be placed 
between the Fc and the transmembrane domain.  An aminoglycoside such as G418, is 
then added 24 hours before selection to promote the surface expression of the POI.  
Aminoglycosides induce readthrough of stop codons in certain contexts, and such an 
system has been used to control expression [220]. 
 
An improved CD4-mimetic peptide 
 Development of the CD4-mimetic peptide.  Our first application of the dual-
display vector was to improve a CD4-mimetic peptide.  Our longer-term goal with this 
effort was the creation of a double-mimetic peptide.  Structural analyses suggested that an 
optimal peptide would initiate with a tyrosine-sulfated CCR5-mimetic peptide fused to 
the N-terminus of the CD4-mimetic peptide.  As a starting point for adaptation and 
improvement, we used a CD4-mimetic peptide with three disulfide bonds, the first of 
which constrains the N-terminus (CD4mim1 in Fig. 3.1B).  Elimination of this first 
disulfide bond gave a weakly active mimetic that served as the starting point for 
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diversification and display (CD4mim2 in Fig. 3.1B).  Initial rounds of panning selected a 
two-disulfide CD4-mimetic with binding properties against clade B envelopes that were 
comparable to those of the three-disulfide version (CD4mim4 in Fig. 3.1B).  
Unexpectedly, and despite the fact that selection was against ADA, a clade B Env, 
binding to clade C Envs was vastly improved over the starting three-disulfide version. 
We speculate that the accidental improvement in breadth was due to increased flexibility 
of the mimetic with only two disulfide bonds. An additional iteration through the process 
yielded a greatly improved CD4-mimetic peptide (CD4mim6 in Fig. 3.1B).  We 
characterized this mimetic peptide for binding and neutralization properties.  As 
described in Chapter 4, we then used this peptide in the creation of double-mimetic 
peptides (Fig. 4.1A).  These studies highlighted a critical weakness of CD4-like 
inhibitors, namely, their parallel tendency to promote infection under some conditions. 
Augmentation of infection by soluble CD4 and CD4-mimetic.  CD4 acts both 
as a primary receptor for HIV-1 and as an attachment factor.  Soluble CD4 (sCD4) is able 
to enhance infection when cell-surface CD4 is limiting, or complement the absence of 
CD4 in a coreceptor-positive cell line [216, 221, 222].  When CD4 is not limiting, sCD4 
interferes with the ability of cellular CD4 to concentrate virus at the cell surface for 
interaction with coreceptor, but it can still enhance infection in cell culture at 
subneutralizing concentrations.  The enhancement at low concentrations (compared to the 
high concentrations necessary for receptor complementation) suggests a trimer 
occupancy model, where occupation of one gp120 induces changes in the trimer as a 
whole, reducing the entropic barrier to the binding not only of coreceptor but also 
perhaps of other CD4 molecules.  Above a certain concentration, multiple occupancy of 
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the trimer by sCD4 molecules is favored and neutralization overcomes enhancement.  
Stated another way, CD4 may induce its own binding, and certainly promotes coreceptor 
association. 
The thermodynamic data we have in support of the conformational masking 
hypothesis all derive from ITC measurements of gp120 binding.  Careful consideration of 
sCD4 enhancement in light of the global rearrangements of various liganded and 
unliganded states observed by Tran et al. suggest a more complicated interplay between 
tertiary and quaternary rearrangements.  The difference between primary isolates and lab-
adapted isolates in CD4-binding is much greater for trimeric Env than for soluble gp120 
[101, 223].  Perhaps there is an additional energy barrier associated with quaternary shifts 
in trimeric Env that is paid by initial binding of one subunit.  For example, the CD4-
bound tertiary structure may be induced in the other gp120 subunits of the trimer when 
CD4 binds a single subunit. 
Like soluble CD4, CD4-mimetic peptides are able to enhance infection and 
complement the absence of cellular CD4.  Also like sCD4, enhancement of infection in 
cell culture is observed at sub-neutralizing concentrations (Fig. 4.3).  Induction of the 
CD4-bound conformation appears to require considerably less contact area than provided 
by CD4.  In the crystal structure of the parental CD4-mimetic F23 bound to gp120, the 
adoption of the CD4-bound conformation is striking.  Nonetheless, in light of the more 
recent structures of the unliganded extended core of gp120, which also adopts the CD4-
bound conformation, the significance of the previous structure is less clear.  However, 
receptor complementation and low concentration enhancement are clear indications that 
our CD4-mimetic peptide induces the CD4-bound state (Figs 3.6A and 4.3).  Perhaps 
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because of the lower affinity, there is a broader more noticeable plateau to this 
enhancement (Fig. 4.3).  Unlike CD4, CD4-mimetic contact with the V1/V2 stem is not 
directly observed, thus any fixation of the bridging sheet would likely have to be 
communicated to topological layer 2 via the α-helix in layer 3 contacts with CD4 Phe43, 
as per the model of Désormeaux el al. [224].  This group found that mutations in layer 3 
at its interface with layer 2 had moderate effects on CD4-binding while abolishing the 
binding of CD4i antibodies.  This model suggests a means of fixing the layer 2 that does 
not require interaction with the V1/V2 stem. 
Improvements to the CD4-mimetic.  The CD4-mimetic peptide is currently of 
insufficient breadth to be considered a viable therapeutic and would benefit from 
maturation against a broader set of Envs, with particular attention paid to the difficult-to-
neutralize tier III envelope glycoproteins.  Currently the linker region of the double-
mimetic peptide is designed to serve only as a flexible, soluble tether between the two 
mimetic peptides.  However, it necessarily traverses the area of CD4 contact with the 
V1/V2 stem, the a1 α-helix [225, 226].  Residues of this linker region of the double-
mimetic peptide could be added to the N-terminus of the CD4-mimetic and then soft-
randomized.  This would create opportunities for creation of useful contacts in a 
conserved region. 
Another potentially useful alteration in the CD4-mimetic would be elimination of 
an additional disulfide bond.  Synthesis of disulfide-cyclized peptides like the CD4-
mimetic increases geometrically in difficulty (and expense) as a second and third 
disulfide bonds are added.  Significantly, the deprotection steps necessary for the 
sequential formation of the second and third disulfide bonds are incompatible with the 
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retention of sulfotyrosines, which are labile under acidic conditions.  The first disulfide 
bond requires no special chemistry whatsoever, and is therefore compatible with the 
synthesis of a tyrosine-sulfated peptide, as in the double-mimetic peptide.  We observed 
gains in breadth associated with the elimination of the first disulfide bond.  It would be 
interesting to observe if a similar gain would be attainable with the elimination of a 
second, or if the entropy penalty for binding the less restricted peptide would be too 
expensive.  We have no indication at this point whether the C6-C24 disulfide (which 
constrains the α-helix) or the disulfide C10-C26 (which constrains the β-hairpin) would 
be better tolerated so libraries for each would be constructed.  
 
The double-mimetic peptide 
Block to augmentation by double mimetic.  Coreceptor-binding site antibodies 
are poorly neutralizing because steric interactions with the target cell membrane prevent 
cooperative binding between cell-surface CD4 and CD4i antibodies.  The CCR5-mimetic 
peptide used here is not subject to this limitation, but it is a weak binder by itself.  The 
CD4-mimetic peptide binds Env more efficiently, but can enhance infection at sub-
neutralizing concentrations.  We found that addition of a CCR5-mimetic to a CD4-
mimetic generated a double-mimetic of greater potency than that of either component 
alone or as a mixture.  Examination of the crystal structures of gp120 bound to a CD4-
mimetic peptide, and of gp120 bound to the tyrosine-sulfated antibody 412d, led us to 
believe that a CCR5-mimetic CD4-mimetic orientation would be optimal [62, 146].  
Indeed in Chapter 4, we proved that to be the case.  However, our analysis was 
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complicated by the multiple possible binding modes of what is essentially a homo-dimer 
(the Fc fusion) of a hetero-dimer (the double-mimetic) binding a trimeric Env target at 
two distinct sites.  To address these issues, we created the first monomeric Fc to appear in 
the literature, which appeared first in Kwong JA et al. [78] (See Fig. 5.1). 
 
Cis and Cis/Trans binding modes.  The double-mimetic peptide is comprised of 
two moieties that bind cooperatively to two different sites on Env.  If the binding partner 
is monomeric gp120, as is the case for IP and SPR assays, there are two different 
potential binding modes, where the receptor- and coreceptor-binding sites are occupied 
by the components of two different molecules of the double-mimetic binding 
cooperatively (so called trans binding, see Fig. 4.4D), or by the two components of the 
Figure 5.1. CCR5mim-Ig but not CD4-Ig binds two monomers of the HIV-1 envelope glycoprotein 
trimer. CD4-Ig, CCR5mim-Ig, CD4mim-Ig, or variants thereof which express as monomeric proteins 
were incubated at approximately half-maximal concentrations (5 nM for CD4-Ig, 50 nM for CD4mim-
Ig and CCR5mim-Ig) with 293T cells expressing the indicated envelope glycoproteins and analyzed by 
flow cytometry. Differences between monomeric and dimeric forms of CCR5mim-Ig and CD4mim-Ig 
in all cases are significant (P<0.005) by Student’s t. Adapted from Fig. 2C of Kwong JA et al. [78] 
using a monomeric Fc domain generated for the studies of Chapter 4 
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same molecule (cis binding).  The situation is complicated further when the double-
mimetic peptide is expressed as a fusion to an IgG1 Fc domain, which is dimeric.  In this 
case, binding can potentially involve the CD4-mimetic from one half of the homodimer, 
and the CCR5-mimetic from the other (cis/trans dimer binding).  We distinguish between 
these modes of binding using a monomeric Fc version of the double-mimetic as a control.  
Using these monomers, we observed differences in binding between optimal and sub-
optimal linker lengths, indicating that cis binding was only achieved with longer linkers.   
Yet another layer of complexity is introduced when the binding partner is trimeric 
Env, as is the case for neutralization or surface-staining assays.  Here a homodimer 
(double mimetic) of a heterodimer (Fc) is binding a homo-trimer (Env), and binding may 
take place with either component of two halves of the Fc binding across the trimer.  
Differentiation between these binding modes is made by inference: monomeric and 
dimeric forms of the single-mimetic components are compared by surface staining assay.  
This evaluation was performed in Kwong JA et al. [78] on earlier versions of the mimetic 
peptides and with CD4-Ig (see Fig. 5.1).  Those data indicate that the two halves of CD4-
Ig could not bind across the trimer, that CD4-mimetic could do so to some extent, but less 
so than CCR5-mimetic.  These data are in good agreement with what can be inferred 
from cryo-EM data.  CD4 binds in the trimer cleft, and projects away from the trimer axis 
in the lateral plane, placing its C-terminus, and its Fc dimer partner far from the other two 
clefts of the trimer.  The C-terminus of CD4 mimetic is much closer to gp120, and two 
flexible linkers, and the free portion of the two Fc hinges, might potentially bridge the 
gap (See Fig. 4.1).  In contrast, the coreceptor-binding sites are grouped at the apex of the 
trimer spike, near the trimer axis of symmetry, easily allowing binding across the trimer. 
87	  
Improvements to the double mimetic peptide.  With adaptation of the pDQ1 
vector to mammalian surface expression, it would also be possible to direct evolution of 
the double-mimetic using this vector.   The CCR5-mimetic, the linker region and the N-
terminal α-helix of the CD4-mimetic would be subject to soft randomization and an 
initial round of selection in phage would select on CD4-binding capacity alone, as no 
tyrosines would be sulfated in this system.  Subsequent rounds of selection would be in a 
mammalian surface display system, with sulfotransferase co-expression.  Selection would 
employ cell-sorting with fluorescently labeled gp120. 
Future of the CCR5-mimetic peptide.  Without significant improvement, CD4-
mimetic based compounds are unlikely to be useful in the clinic.  CD4mim6 is probably 
adequate for most non-clinical use of mimetic peptide as a tool.  On the other hand, it has 
been demonstrated in our lab that a CD4-Fc with a CCR5 element fused to it is a very 
potent immunoadhesin with an exceptionally broad range of neutralization across all 
clades and tiers of HIV-1 and even HIV-2 and SIV (Gardner et al., submitted). Thus 
improvement of the CCR5-mimetic peptide is of greater relevance.   
One could improve this fusion directly with a mammalian display system.  The 
CCR5-mimetic peptide of this potent CD4-Fc-CCR5mim construct is fused to the C-
terminus of Fc.  To evolve this peptide in the proper context one would want to display it 
on the cell-surface with an N-terminal rather than C-terminal membrane anchor, in a type 
II membrane protein configuration.  The topological morphologies of type I and type II 
membrane proteins are quite similar, the only difference is that a type II membrane 
protein lacks a signal-peptidase cleavage site in what is then the signal anchor (the type II 
trans-membrane domain), and, unlike type I transmembrane domains, there is no stop 
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anchor at the C-terminus.  Otherwise, the orientation of engagement with the signal 
recognition particle, and the translocation of the growing peptide across the membrane 
are identical.  The N-terminus of CD4 enters domain one (D1) near the junction with 
domain two (D2), away from the site of gp120 binding.  A type II signal anchor (such as 
from the transferrin receptor) followed by a sufficiently long anchor should allow for 
display of a CD4-Fc construct with unconstrained binding of an N-terminally anchored 
CD4, followed by the Fc and a free C-terminal CCR5-mimetic peptide.  Diversification 
would be focused on the CCR5-mimetic element.  To emulate genuine trimer binding, 
fluorescently labeled virus would be used as bait, and selection would be by cell sorting 
on the fluorophore. 
However, given the great difference in affinity between the CCR5-mimetic 
peptide and sCD4, the double-mimetic peptide might be the preferred platform for 
directed evolution of CCR5-mimetic peptide.  Variation would be restricted to the CCR5-
mimetic component, and selection would be by cell surface binding.  An advantage to the 
double-mimetic in this context is that the CCR5-mimetic is N-terminal, thus any library 
components containing frameshifts could be removed through an initial round of phage 
display, with subsequent rounds of mammalian display selecting for differences in 
binding between variants.  Alternatively, the CCR5-mimetic could be improved 
independently by mammalian display with induction by sCD4 provided in trans during 
selection. 
A system exists for the display of sulfotyrosines in phage using a sulfotyrosine 
amber suppressor codon [219, 227].  This approach could indeed be used for evolution of 
CCR5-mimetic peptides.   However, because the sulfotyrosines are hard-coded, there is 
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no guarantee that outputs would correspond to sequence that would be sulfated in a 
mammalian expression system.  One possible way around this difficulty might be to bias 
towards retention of sulfation motifs by excluding hydrophobic or positively charges 
amino acids, though this would necessarily involve the exclusion or reduction of glutamic 
acid and glycine; both of these amino acids compatible with, and in the case of glycine 
critical for, sulfation.  The dual-display pDQ1 system could not be used with this system 
because amber-encoded sulfotyrosines would translate as stop codons when transferred to 
the mammalian system. 
 
Modeling escape pathways 
The current work has concentrated on the development of HIV-1 entry inhibitors, 
and points the way towards directed evolution of other, potentially more potent 
immunoadhesins.  However, an equally interesting and relatively unexplored application 
of these controlled diversification and selection techniques would be to model the viral 
side of the conflict. 
Directed Evolution of Env.  The HIV-1 virus is adept at adapting itself to the 
changing immune environment of the host over the course of infection. In longitudinal 
studies of virus and antibody populations, contemporaneous virus is resistant to 
neutralization whereas virus at earlier time points is sensitive [228].  Adaptation to 
broadly neutralizing antibodies comes at a fitness cost, and virus resistant to CD4bs 
bNAbs replicates poorly due to a reduced ability to bind CD4 [229].  In the development 
of antibody-based therapeutic approaches, it is important to be able to identify cocktails 
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of antibodies to which, in combination, would close off all avenues of escape [230].  
Such in vitro checkmate analysis could save years of study in an expensive animal model. 
As a model for viral escape, simple passage in cell culture in the presence of 
bNAbs is inadequate.  Passage in cell-culture leads to non-physiologically relevant 
changes in Env including truncations in V1/V2, and other changes that lead to a open Env 
trimer conformation and less masking of epitopes [74, 129, 216, 231, 232].  Moreover, 
typically only a single mutation emerges to overgrow a culture under selection.  Also, the 
endogenous diversification of the virus is inadequate to a compressed time-scale.   The 
fidelity of the viral polymerase is tuned to balance the need to generate viable progeny 
with the need to generate the diversity necessary for rapid adaptation.  Introduction of a 
higher mutation rate, for example by the restriction factor APOBEC3G, pushes this 
balance towards catastrophe [233].  Furthermore, mutation due to polymerase infidelity 
gives no preference to potentially relevant mutations.  Mutations in viral proteins other 
than Env are much more likely to be deleterious, and with no potential to further escape 
from bNAbs.  In contrast, with directed in vitro diversification model, non-random 
mutations can be tolerated at a significantly higher rate. 
By concentrating randomization in the one gene relevant for escape, a controlled 
diversification technique can be used to explore a large sequence space in a much shorter 
period than the virus could arrive at on its own.   It is useful to further exclude from 
diversification highly conserved residues of Env, thereby increasing the ratio of 
potentially adaptive to deleterious mutations.  Ideally one would want to construct groups 
of libraries randomizing unconstrained residues in two different areas of Env, such that 
every combination of two mutations would be covered.  Initial diversity could be 
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evaluated by next-generation sequencing.  Serial passage of libraries at low to moderate 
MOI would eliminate the free-rider effect caused by co-transfection.  These virus 
libraries would then be screened against individual neutralizing antibodies, or against 
optimized cocktails of such antibodies, providing accelerated insight into viable escape 
pathways.  Given time, rare events such as deletions and insertions give the virus means 
towards escape that would fall outside the model.  Nevertheless, it should be possible to 
differentiate between antibodies and antibody cocktail by ease of escape.  Application of 
the model to antibodies and cocktails that are already under study in primates would 
allow for testing of the predictive value of the system. 
 
Closing Remarks 
In the conflict between HIV-1 quasispecies and host antibody repertoire the virus 
holds the distinct advantage.  Viral diversification is faster than somatic hypermutation, 
and viral replication outpaces clonal expansion.  The virus provides very few non-moving 
targets, and distracts immune recognition away from these conserved sites.  When 
recognition does occur, such as in the subset (10-30%) of patients who develop bNAbs in 
their repertoire, it is not clear that this can happen in time to significantly affect disease 
progression [98, 234, 235].  However, these bNAbs do indicate points of vulnerability for 
the virus and serve as starting points for therapeutic development.  The broadest 
antibodies identified so far are directed against the CD4-binding site.  Our experience in 
constructing the double-mimetic peptide highlights the gains to be had in a coordinated 
attack on the CD4- and coreceptor-binding sites, and demonstrate the potential utility of a 
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peptide targeting the coreceptor-binding site, despite its low activity by itself.  In our 
experience with directed evolution of the CD4-mimetic peptide, we are struck by the 
robustness of the diversification techniques and display tools that we have adopted and 
improved.   We expect these tools to be of use in developing a new generation of 
antibodies and immunoadhesin cocktails.  In parallel, analogous directed diversification 
techniques applied to Env may assist in checkmate analysis of such agents in blocking 
viral evolution and escape.
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